<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Hepatic late adverse effects after antineoplastic treatment for childhood cancer - Mulder, RL - 2019 | Cochrane Library</title> <meta content="Hepatic late adverse effects after antineoplastic treatment for childhood cancer - Mulder, RL - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008205.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Hepatic late adverse effects after antineoplastic treatment for childhood cancer - Mulder, RL - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008205.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008205.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Hepatic late adverse effects after antineoplastic treatment for childhood cancer" name="citation_title"/> <meta content="Renée L Mulder" name="citation_author"/> <meta content="r.l.mulder@prinsesmaximacentrum.nl" name="citation_author_email"/> <meta content="Dorine Bresters" name="citation_author"/> <meta content="Malon Van den Hof" name="citation_author"/> <meta content="Emma Children's Hospital, Amsterdam UMC, University of Amsterdam" name="citation_author_institution"/> <meta content="Bart GP Koot" name="citation_author"/> <meta content="Emma Children's Hospital, Amsterdam UMC, University of Amsterdam" name="citation_author_institution"/> <meta content="Sharon M Castellino" name="citation_author"/> <meta content="Emory School of Medicine" name="citation_author_institution"/> <meta content="Yoon Kong K Loke" name="citation_author"/> <meta content="University of East Anglia" name="citation_author_institution"/> <meta content="Piet N Post" name="citation_author"/> <meta content="Dutch Institute for Healthcare Improvement CBO" name="citation_author_institution"/> <meta content="Aleida Postma" name="citation_author"/> <meta content="University Medical Center Groningen and University of Groningen, Beatrix Children's Hospital" name="citation_author_institution"/> <meta content="László P Szőnyi" name="citation_author"/> <meta content="King Feisal Specialist Hospital" name="citation_author_institution"/> <meta content="Gill A Levitt" name="citation_author"/> <meta content="Great Ormond Street Hospital for Children NHS Foundation Trust" name="citation_author_institution"/> <meta content="Edit Bardi" name="citation_author"/> <meta content="Kepler Universitätsklinikum" name="citation_author_institution"/> <meta content="Roderick Skinner" name="citation_author"/> <meta content="Great North Children’s Hospital" name="citation_author_institution"/> <meta content="Elvira C van Dalen" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD008205.pub3" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/04/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008205.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008205.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008205.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Chemical and Drug Induced Liver Injury; Alanine Transaminase [metabolism]; Antineoplastic Agents [*adverse effects, therapeutic use]; Liver Diseases; Neoplasms [*drug therapy, *radiotherapy]; Radiotherapy [*adverse effects]; gamma‐Glutamyltransferase [metabolism]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008205.pub3&amp;doi=10.1002/14651858.CD008205.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008205.pub3&amp;doi=10.1002/14651858.CD008205.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008205.pub3&amp;doi=10.1002/14651858.CD008205.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008205.pub3&amp;doi=10.1002/14651858.CD008205.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008205.pub3&amp;doi=10.1002/14651858.CD008205.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008205.pub3&amp;doi=10.1002/14651858.CD008205.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008205.pub3&amp;doi=10.1002/14651858.CD008205.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008205.pub3&amp;doi=10.1002/14651858.CD008205.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008205.pub3&amp;doi=10.1002/14651858.CD008205.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008205.pub3&amp;doi=10.1002/14651858.CD008205.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008205.pub3&amp;doi=10.1002/14651858.CD008205.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008205.pub3&amp;doi=10.1002/14651858.CD008205.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008205.pub3&amp;doi=10.1002/14651858.CD008205.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008205.pub3&amp;doi=10.1002/14651858.CD008205.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008205.pub3&amp;doi=10.1002/14651858.CD008205.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008205.pub3&amp;doi=10.1002/14651858.CD008205.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008205.pub3&amp;doi=10.1002/14651858.CD008205.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008205.pub3&amp;doi=10.1002/14651858.CD008205.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008205.pub3&amp;doi=10.1002/14651858.CD008205.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008205.pub3&amp;doi=10.1002/14651858.CD008205.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008205.pub3&amp;doi=10.1002/14651858.CD008205.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008205.pub3&amp;doi=10.1002/14651858.CD008205.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008205.pub3&amp;doi=10.1002/14651858.CD008205.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="6iOnQIUh";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008205\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008205\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008205\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008205\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ms","fa","fr","hr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008205.pub3",title:"Hepatic late adverse effects after antineoplastic treatment for childhood cancer",firstPublishedDate:"Apr 15, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Childhood Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6iOnQIUh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008205.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008205.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008205.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008205.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008205.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008205.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008205.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008205.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008205.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008205.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3335 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008205.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/full#CD008205-abs-0006"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/full#CD008205-sec-0068"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/full#CD008205-sec-0036"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/full#CD008205-sec-0037"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/full#CD008205-sec-0038"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/full#CD008205-sec-0056"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/full#CD008205-sec-0067"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/appendices#CD008205-sec-0072"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Hepatic late adverse effects after antineoplastic treatment for childhood cancer</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/information#CD008205-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Renée L Mulder</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/information#CD008205-cr-0003">Dorine Bresters</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/information#CD008205-cr-0004">Malon Van den Hof</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/information#CD008205-cr-0005">Bart GP Koot</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/information#CD008205-cr-0006">Sharon M Castellino</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/information#CD008205-cr-0007">Yoon Kong K Loke</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/information#CD008205-cr-0008">Piet N Post</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/information#CD008205-cr-0009">Aleida Postma</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/information#CD008205-cr-0010">László P Szőnyi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/information#CD008205-cr-0011">Gill A Levitt</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/information#CD008205-cr-0012">Edit Bardi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/information#CD008205-cr-0013">Roderick Skinner</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008205.pub3/information#CD008205-cr-0014">Elvira C van Dalen</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/information/en#CD008205-sec-0080">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 April 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008205.pub3">https://doi.org/10.1002/14651858.CD008205.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008205-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008205-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008205-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008205-abs-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008205-abs-0004">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008205-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008205-abs-0001" lang="en"> <section id="CD008205-sec-0001"> <h3 class="title" id="CD008205-sec-0001">Background</h3> <p>Survival rates have greatly improved as a result of more effective treatments for childhood cancer. Unfortunately, the improved prognosis has been accompanied by the occurrence of late, treatment‐related complications. Liver complications are common during and soon after treatment for childhood cancer. However, among long‐term childhood cancer survivors, the risk of hepatic late adverse effects is largely unknown. To make informed decisions about future cancer treatment and follow‐up policies, it is important to know the risk of, and associated risk factors for, hepatic late adverse effects. This review is an update of a previously published Cochrane review. </p> </section> <section id="CD008205-sec-0002"> <h3 class="title" id="CD008205-sec-0002">Objectives</h3> <p>To evaluate all the existing evidence on the association between antineoplastic treatment (that is, chemotherapy, radiotherapy involving the liver, surgery involving the liver and BMT) for childhood cancer and hepatic late adverse effects. </p> </section> <section id="CD008205-sec-0003"> <h3 class="title" id="CD008205-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i> 2018, Issue 1), MEDLINE (1966 to January 2018) and Embase (1980 to January 2018). In addition, we searched reference lists of relevant articles and scanned the conference proceedings of the International Society of Paediatric Oncology (SIOP) (from 2005 to 2017) and American Society of Pediatric Hematology/Oncology (ASPHO) (from 2013 to 2018) electronically. </p> </section> <section id="CD008205-sec-0004"> <h3 class="title" id="CD008205-sec-0004">Selection criteria</h3> <p>All studies, except case reports, case series, and studies including fewer than 10 patients that examined the association between antineoplastic treatment for childhood cancer (aged 18 years or less at diagnosis) and hepatic late adverse effects (one year or more after the end of treatment). </p> </section> <section id="CD008205-sec-0005"> <h3 class="title" id="CD008205-sec-0005">Data collection and analysis</h3> <p>Two review authors independently performed the study selection and 'risk of bias' assessment. The 'risk of bias' assessment was based on earlier checklists for observational studies. For the original version of the review, two review authors independently performed data extraction. For the update of the review, the data extraction was performed by one reviewer and checked by another reviewer. </p> </section> <section id="CD008205-sec-0006"> <h3 class="title" id="CD008205-sec-0006">Main results</h3> <p>Thirteen new studies were identified for the update of this review. In total, we included 33 cohort studies including 7876 participants investigating hepatic late adverse effects after antineoplastic treatment (especially chemotherapy and radiotherapy) for different types of childhood cancer, both haematological and solid malignancies. All studies had methodological limitations. The prevalence of hepatic late adverse effects, all defined in a biochemical way, varied widely, between 0% and 84.2%. Selecting studies where the outcome of hepatic late adverse effects was well‐defined as alanine aminotransferase (ALT) above the upper limit of normal, indicating cellular liver injury, resulted in eight studies. In this subgroup, the prevalence of hepatic late adverse effects ranged from 5.8% to 52.8%, with median follow‐up durations varying from three to 23 years since cancer diagnosis in studies that reported the median follow‐up duration. A more stringent selection process using the outcome definition of ALT as above twice the upper limit of normal, resulted in five studies, with a prevalence ranging from 0.9% to 44.8%. One study investigated biliary tract injury, defined as gamma‐glutamyltransferase (γGT) above the upper limit of normal and above twice the upper limit of normal and reported a prevalence of 5.3% and 0.9%, respectively. Three studies investigated disturbance in biliary function, defined as bilirubin above the upper limit of normal and reported prevalences ranging from 0% to 8.7%. Two studies showed that treatment with radiotherapy involving the liver (especially after a high percentage of the liver irradiated), higher BMI, and longer follow‐up time or older age at evaluation increased the risk of cellular liver injury in multivariable analyses. In addition, there was some suggestion that busulfan, thioguanine, hepatic surgery, chronic viral hepatitis C, metabolic syndrome, use of statins, non‐Hispanic white ethnicity, and higher alcohol intake (&gt; 14 units per week) increase the risk of cellular liver injury in multivariable analyses. Chronic viral hepatitis was shown to increase the risk of cellular liver injury in six univariable analyses as well. Moreover, one study showed that treatment with radiotherapy involving the liver, higher BMI, higher alcohol intake (&gt; 14 units per week), longer follow‐up time, and older age at cancer diagnosis increased the risk of biliary tract injury in a multivariable analysis. </p> </section> <section id="CD008205-sec-0007"> <h3 class="title" id="CD008205-sec-0007">Authors' conclusions</h3> <p>The prevalence of hepatic late adverse effects among studies with an adequate outcome definition varied considerably from 1% to 53%. Evidence suggests that radiotherapy involving the liver, higher BMI, chronic viral hepatitis and longer follow‐up time or older age at follow‐up increase the risk of hepatic late adverse effects. In addition, there may be a suggestion that busulfan, thioguanine, hepatic surgery, higher alcohol intake (&gt;14 units per week), metabolic syndrome, use of statins, non‐Hispanic white ethnicity, and older age at cancer diagnosis increase the risk of hepatic late adverse effects. High‐quality studies are needed to evaluate the effects of different therapy doses, time trends, and associated risk factors after antineoplastic treatment for childhood cancer. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008205-abs-0006" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008205-abs-0006">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008205-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008205-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008205-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008205-abs-0013">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008205-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008205-abs-0007">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD008205-abs-0008">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008205-abs-0006" lang="en"> <h3>Adverse effects on the liver after treatment for childhood cancer</h3> <p><b>Review question</b> </p> <p>We reviewed the evidence for the effects of treatment for childhood cancer on the risk of adverse effects on the liver. </p> <p><b>Background</b> </p> <p>Advances in the treatment of childhood cancer over the last decades have greatly improved the survival rates. Unfortunately, the improved prognosis has been accompanied by the occurrence of late, treatment‐related complications. One of the adverse effects that can occur due to treatment of childhood cancer is damage to the liver. Liver adverse effects are common both during and soon after treatment. However, the evidence on adverse effects on the liver many years after treatment is still inconclusive. Adverse effect on the liver as a result of childhood cancer treatment is most often subclinical (asymptomatic). If liver disease becomes symptomatic, a person's complaints may include fatigue, jaundice, nausea, weight loss, and abdominal pain. The development of future treatment and follow‐up policies should be based on high‐quality evidence on the risk of, and associated risk factors for, adverse effects on the liver. </p> <p><b>Study characteristics</b> </p> <p>The evidence is current to January 2018.</p> <p>We found 33 cohort studies examining liver adverse effects after treatment for childhood cancer. There were 7876 cancer patients included that were treated for different types of childhood cancer, especially with chemotherapy, radiotherapy, and bone marrow transplantation. The average follow‐up duration in the studies that reported this varied from two years after the end of treatment to 25 years since primary cancer diagnosis. </p> <p><b>Key results</b> </p> <p>We found that 1% to 53% of the childhood cancer survivors developed adverse effects on the liver after cancer treatment, measured by liver enzymes in the blood. Radiotherapy to the liver increases the risk of liver late adverse effects. In addition, busulfan, thioguanine, or liver surgery may increase the risk as well. Also, survivors with chronic viral hepatitis, metabolic syndrome, higher body mass index, higher alcohol intake, statin use, non‐Hispanic white ethnicity, longer time since cancer diagnosis, and older age at cancer diagnosis seemed to have an increased risk of liver adverse effects. </p> <p><b>Quality of the evidence</b> </p> <p>All studies had problems related to the quality of the evidence.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008205-sec-0068" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008205-sec-0068"></div> <h3 class="title" id="CD008205-sec-0069">Implications for practice</h3> <section id="CD008205-sec-0069"> <p>This systematic review shows that childhood cancer survivors are at risk for hepatic late adverse effects defined as ALT above the upper limit of normal. Evaluation of serum ALT level could be helpful to screen early for hepatic late adverse effects. Abnormalities should initiate additional evaluation and measurement to prevent any further damage. Based on the results of this systematic review, it might be rational to monitor childhood cancer survivors treated with radiotherapy involving the liver, busulfan, thioguanine and/or hepatic surgery. Recommendations about the time interval of evaluation and the importance of other tests cannot be made based on currently available evidence. One should keep in mind: no evidence of effect does not mean evidence of no effect. As more data become available, clinicians will be able to make better‐informed decisions regarding the treatment of future childhood cancer patients and to develop targeted follow‐up programs for survivors. Since liver disease can be indolent, it might be rational that counselling should be provided regarding preventive behaviours like avoidance of alcohol, immunization against hepatitis A and B, and cautious use of alternative therapies that have a risk of liver injury. </p> </section> <h3 class="title" id="CD008205-sec-0070">Implications for research</h3> <section id="CD008205-sec-0070"> <p>Based on the results of this systematic review, high‐quality studies in childhood cancer survivors are needed to: 1) evaluate the exact radiotherapy and chemotherapy threshold doses for developing hepatic late adverse effects; 2) evaluate the possible joint effects of radiation dose and radiation volume on the risk of hepatic late adverse effects; 3) evaluate the impact of aging on the risk of hepatic late adverse effects; 4) evaluate the influence of other determinants on the risk of hepatic late adverse effects, such as haematopoietic stem cell transplant, steatosis, SOS, iron overload, and GVHD; 5) evaluate time trends and associated risk factors for hepatic late adverse effects; 6) evaluate the predictive value of first assessment on hepatic late adverse effects time trends; 7) evaluate the prognostic value of subclinical hepatic late adverse effects for developing clinical disease. In addition, since many of the studies are quite dated and the epidemiology of chronic viral hepatitis has changed, more current data is needed. Ideally, future studies should longitudinally evaluate liver health in all children treated for cancer. Follow‐up should be long enough and complete with precise and uniform outcome definitions, including transaminases and synthetic indicators of liver function. The development of imaging modalities which may lead to non‐invasive characterisation of the liver also holds promise for this population. While the cancer survivor has many end organ risks after therapy, it remains to be investigated whether the unique regenerative capacity of the liver obviates follow‐up for hepatic late adverse effects or whether certain host or therapy exposures lead to threshold effects for late liver injury. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008205-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008205-sec-0036"></div> <p>Survival rates have greatly improved as a result of more effective treatments for childhood cancer. Today, most children diagnosed with cancer are expected to become long‐term cancer survivors (<a href="#CD008205-bbs2-0265">Curry 2006</a>). Five‐year disease‐free survival now reaches 80% in Europe (<a href="#CD008205-bbs2-0268">Gatta 2009</a>). Unfortunately, the improved prognosis has been accompanied by the occurrence of late, treatment‐related complications. In two large cohort studies of childhood cancer survivors, nearly 75% experienced one or more late adverse effects (<a href="#CD008205-bbs2-0269">Geenen 2007</a>; <a href="#CD008205-bbs2-0183">Oeffinger 2006</a>). </p> <p>Liver complications are common during and soon after treatment for childhood cancer (<a href="#CD008205-bbs2-0267">Field 2008</a>). However, among long‐term childhood cancer survivors the prevalence of chronic liver disease, like fibrosis, cirrhosis and consequently an increased risk of decompensated cirrhosis, malignancies and liver failure, is largely unknown. It has been suggested that survivors of childhood cancer who received chemotherapy, particularly methotrexate, 6‐mercaptopurine, 6‐thioguanine, busulphan and dactinomycin; bone marrow transplantation (BMT); radiotherapy involving the liver, including total body irradiation (TBI); or hepatectomy ((partial) removal of the liver) are at risk for developing hepatic late adverse effects (<a href="#CD008205-bbs2-0004">Bresters 2008</a>; <a href="#CD008205-bbs2-0060">Castellino 2010</a>; <a href="#CD008205-bbs2-0266">Dawson 2005</a>; <a href="#CD008205-bbs2-0274">King 2001</a>). However, the evidence has been inconclusive. </p> <p>The aetiology (set of causes) of chronic liver disease following treatment for childhood cancer is complex as often more than one aetiologic factor is present. In addition to cancer treatment, other causes of chronic liver disease have been suggested, such as chronic viral hepatitis, iron overload, and potentially sinusoidal obstruction syndrome (SOS, previously termed veno‐occlusive disease (VOD)) and graft‐versus‐host disease (GVHD) (<a href="#CD008205-bbs2-0278">Locasciulli 1997</a>; <a href="#CD008205-bbs2-0283">Rizzo 2006</a>; <a href="#CD008205-bbs2-0287">Strasser 1999</a>). Regarding chronic viral hepatitis, patients who were treated for childhood cancer before effective hepatitis C virus (HCV) donor screening was implemented are especially at risk for transfusion‐acquired HCV infection. Childhood cancer survivors differ from other groups with chronic viral hepatitis in that they acquired the infection at a young age and were likely to have received immunosuppressive or hepatotoxic therapy (<a href="#CD008205-bbs2-0088">Fink 1993</a>; <a href="#CD008205-bbs2-0288">Strickland 2000</a>). </p> <p>For better development of primary and secondary hepatic protective strategies in childhood cancer, more insight into the association between cancer treatment and hepatic late adverse effects is essential. Furthermore, for the follow‐up of childhood cancer survivors, it is crucial to know the risk and associated risk factors so that patients at greatest risk can be identified and adequate follow‐up protocols established to reduce the consequences of hepatic late adverse effects. With increased survival duration after cancer, survivors are at risk for second malignancies and normal diseases of aging which will require additional pharmacotherapy. This additional morbidity risk also underscores the need for understanding the state of liver health in the long‐term survivor of a childhood cancer, as long‐term impaired liver function may limit treatment of other late effects, like second malignancies. </p> <p>This is an update of the first systematic review evaluating the state of evidence on hepatic late adverse effects after antineoplastic (acting against cancer) treatment for childhood cancer (<a href="#CD008205-bbs2-0291">Mulder 2011</a>). </p> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008205-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008205-sec-0037"></div> <p>To evaluate all the existing evidence on the association between antineoplastic treatment (that is chemotherapy, radiotherapy involving the liver, surgery involving the liver and BMT) for childhood cancer and hepatic late adverse effects. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008205-sec-0038" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008205-sec-0038"></div> <section id="CD008205-sec-0039"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008205-sec-0040"> <h4 class="title">Types of studies</h4> <p>All study designs except case reports, case series (that is, description of non‐consecutive cases) and studies including fewer than 10 participants that examined the association between antineoplastic treatment for childhood cancer and hepatic late adverse effects. </p> </section> <section id="CD008205-sec-0041"> <h4 class="title">Types of participants</h4> <p>Childhood cancer survivors, diagnosed between the age of 0 and 18 years, who were at least one year after the end of their cancer treatment. More than 50% of the study group should have been diagnosed with a malignant disease. More than 50% of the study group should have been diagnosed between the age of 0 and 18 years. In addition, more than 50% of the study group should have been off treatment for at least one year. Because the aim of this systematic review was to evaluate the risk of, and associated risk factors for, hepatic late adverse effects after antineoplastic treatment for childhood cancer, we excluded studies in which the study population consisted solely of childhood cancer survivors with chronic viral hepatitis. In this way, it was possible to reliably evaluate risk factors for hepatic late adverse effects after cancer treatment. </p> </section> <section id="CD008205-sec-0042"> <h4 class="title">Types of interventions</h4> <p>Treatment with chemotherapy, radiotherapy involving the liver (including TBI), surgery involving the liver, or BMT. Liver transplantations were excluded. </p> </section> <section id="CD008205-sec-0043"> <h4 class="title">Types of outcome measures</h4> <p>Hepatic late adverse effects measured by liver enzymes (that is, alanine aminotransferase (ALT), also known as glutamic pyruvic transaminase (SGPT) and aspartate aminotransferase (AST), also known as glutamic oxaloacetic transaminase (SGOT)) to investigate cellular liver injury, and gamma‐glutamyltransferase (γGT)) and alkaline phosphatase (ALP) or bilirubin, to investigate disturbances in bile excretion and biliary tract injury. In addition, measures of liver synthetic function were included: coagulation times (prothrombin time (PTT) or activated partial thromboplastin time (APTT)), albumin, or liver histology. These clinically relevant outcome measures were selected as recommended by an expert in the field (BK). In this review, we used the cut‐off limit for normal and abnormal liver enzyme values as specified by the authors of the original studies. </p> </section> </section> <section id="CD008205-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008205-sec-0045"> <h4 class="title">Electronic searches</h4> <p>The following electronic databases were searched: the Cochrane Central Library of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i> 2018, Issue 1), MEDLINE (PubMed) (from 1945 to 9 January 2018) and Embase (Ovid) (from 1980 to 9 January 2018). The sensitive search strategies used for CENTRAL, MEDLINE, and Embase are presented in <a href="./appendices#CD008205-sec-0073">Appendix 1</a>, <a href="./appendices#CD008205-sec-0074">Appendix 2</a> and <a href="./appendices#CD008205-sec-0075">Appendix 3</a>. </p> </section> <section id="CD008205-sec-0046"> <h4 class="title">Searching other resources</h4> <p>The reference lists of all relevant articles and reviews were screened for additional references which were not registered in CENTRAL, MEDLINE or Embase. We also scanned the conference proceedings of the International Society of Paediatric Oncology (SIOP) (from 2005 to 2017) and American Society of Pediatric Hematology/Oncology (ASPHO) (from 2013 to 2018) electronically (see <a href="./appendices#CD008205-sec-0076">Appendix 4</a>). </p> <p>We did not impose language restrictions.</p> </section> </section> <section id="CD008205-sec-0047"> <h3 class="title" id="CD008205-sec-0047">Data collection and analysis</h3> <section id="CD008205-sec-0048"> <h4 class="title">Selection of studies</h4> <p>After performing the search strategy described previously, two review authors independently selected studies that met the inclusion criteria. Discrepancies between review authors were resolved by consensus. If this was impossible, we achieved final resolution using a third‐party arbitrator. We obtained the full text of any study seemingly meeting the inclusion criteria on the grounds of the title or abstract, or both, for closer inspection. We clearly stated the details of our reasons for exclusion of any study considered for this review. </p> </section> <section id="CD008205-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>For the original version of the review, two review authors independently performed data extraction using standardised forms. For the update of the review, the data extraction was performed by one reviewer and checked by another reviewer. The following data were extracted: study design, original cohort, described study group, study group of interest, study group with liver function testing, control group (if applicable), patient characteristics (including age, gender, body mass index (BMI), tumour type, years of survival, acute liver disease, and hepatitis virus infection), cancer treatment (including chemotherapy, radiotherapy involving the liver, BMT, and hepatectomy), duration and completion of follow‐up, hepatic late adverse effects (including method of detection, definition, and outcome measure) and risk factors. In case of disagreement, a third review author was consulted. </p> <p>We defined cohort studies as studies in which a group of consecutive patients treated for childhood cancer was followed from a similar well‐defined point in the course of the disease (x‐year survivors). The described study group could be the entire original cohort of childhood cancer survivors or a subgroup of the original cohort, based on well‐defined inclusion criteria. </p> <p>The participants in the original cohort represented the whole group of childhood cancer survivors. The described study group encompassed the childhood cancer survivors from the original cohort included in the study. The study group of interest was the childhood cancer survivors within the original cohort who received treatment with a high potential for hepatic late adverse effects. Finally, the study group with liver function testing was the childhood cancer survivors who were assessed for hepatic late adverse effects as well. </p> </section> <section id="CD008205-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The assessment of risk of bias was based on earlier described checklists for observational studies according to Evidence‐Based Medicine Criteria (<a href="#CD008205-bbs2-0270">Grimes 2002</a>; <a href="#CD008205-bbs2-0276">Laupacis 1994</a>). Two review authors independently undertook the assessment of risk of bias of the included studies, concerning the selection of the study group, the follow‐up and outcome assessments, and the methods used for risk estimation. For evaluation of internal validity, we assessed the risk of selection bias, attrition bias, detection bias, and confounding that was present in the included studies. It included the following items: representativeness of the study group, completeness of the follow‐up, blinding of the outcome assessors, and adjustment for important confounding factors. We only assessed the risk of confounding for studies that reported on risk factors. For evaluation of external validity, we assessed the risk of reporting bias, which included the following items: definition of the study group, reporting the length of follow‐up, objectiveness of the outcome definition, and definition of the analyses. We only assessed the definition of the analyses for studies that reported on risk factors.The 'risk of bias' assessment criteria for observational studies are described in additional <a href="#CD008205-tbl-0001">Table 1</a>. Discrepancies between review authors were resolved by consensus. In case of doubt, a third review author was consulted. </p> <div class="table" id="CD008205-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Risk of bias assessment criteria for observational studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Internal validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>External validity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study group </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Selection bias (representative: yes/no)</p> <p> <ul id="CD008205-list-0001"> <li> <p>if the described study group consisted of more than 90% of the original cohort of childhood cancer survivors </p> </li> <li> <p><i>or</i> if it was a random sample with respect to the cancer treatment </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reporting bias (well defined: yes/no)</p> <p> <ul id="CD008205-list-0002"> <li> <p>if the type of chemotherapy and/or location of radiotherapy was mentioned</p> </li> <li> <p><i>and</i> if the number of participants with chronic viral hepatitis was mentioned </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Follow‐up </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Attrition bias (adequate: yes/no)</p> <p> <ul id="CD008205-list-0003"> <li> <p>if the outcome was assessed for more than 90% of the study group of interest (++)</p> </li> <li> <p><i>or</i> if the outcome was assessed for 60% to 90% of the study group of interest (+) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reporting bias (well defined: yes/no)</p> <p> <ul id="CD008205-list-0004"> <li> <p>if the length of follow‐up was mentioned</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome     </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Detection bias (blind: yes/no)</p> <p> <ul id="CD008205-list-0005"> <li> <p>if the outcome assessors were blinded to the investigated determinant (if outcomes are biochemical measurements produced by a machine, blinding of the investigator is not relevant) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reporting bias (well‐defined: yes/no)</p> <p> <ul id="CD008205-list-0006"> <li> <p>if the outcome definition was objective and precise, i.e. if the upper limits of normal for liver function tests were described in the definition of hepatic late adverse effects </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk estimation </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confounding (adjustment for other factors: yes/no)</p> <p> <ul id="CD008205-list-0007"> <li> <p>if important prognostic factors (i.e. age, gender, co‐treatment) or follow‐up were taken adequately into account </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Analyses (well‐defined: yes/no)</p> <p> <ul id="CD008205-list-0008"> <li> <p>if a relative risk, odds ratio, attributable risk, linear or logistic regression model, mean difference or Chi<sup>2</sup> was calculated </p> </li> </ul> </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD008205-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>Prevalence, cumulative incidence, mean difference, relative risk, odds ratio, attributable risk, and other associated outcomes. </p> </section> <section id="CD008205-sec-0052"> <h4 class="title">Assessment of heterogeneity</h4> <p>Heterogeneity was assessed by visual inspection of the tables. If there was evidence of substantial heterogeneity (I<sup>2</sup> &gt; 50%) (<a href="#CD008205-bbs2-0271">Higgins 2011</a>), this was reported. </p> </section> <section id="CD008205-sec-0053"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to construct a funnel plot to graphically ascertain the existence of publication bias. A rule of thumb is that tests for funnel plot asymmetry are used only when there are at least 10 studies in the meta‐analysis. In the event of fewer than 10 studies, the power of the test is too low to distinguish chance from real asymmetry (<a href="#CD008205-bbs2-0271">Higgins 2011</a>). Given that none of the included studies in the current analysis were pooled, we could not construct funnel plots. </p> </section> <section id="CD008205-sec-0054"> <h4 class="title">Data synthesis</h4> <p>Data were entered into RevMan (<a href="#CD008205-bbs2-0292">Review Manager 2014</a>) and analysed according to the guidelines of the <i>Cochrane Handbook</i> (<a href="#CD008205-bbs2-0271">Higgins 2011</a>). All results are presented with the corresponding 95% confidence interval (95% CI), as calculated by the Wilson method. As this was not possible in RevMan, we used the following tool: http://epitools.ausvet.com.au/content.php?page=CIProportion. Because pooling was not possible due to substantial heterogeneity, we provided descriptive results of these studies. </p> </section> <section id="CD008205-sec-0055"> <h4 class="title">Sensitivity analysis</h4> <p>We did not perform sensitivity analyses since pooling was not possible for any of the outcomes. We did take into account the risk of bias in studies included in this systematic review in the interpretation of the results. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008205-sec-0056" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008205-sec-0056"></div> <section id="CD008205-sec-0057"> <h3 class="title">Description of studies</h3> <section id="CD008205-sec-0058"> <h4 class="title">Results of the search</h4> <p>See: <a href="./references#CD008205-sec-0086" title="">Characteristics of included studies</a>; <a href="./references#CD008205-sec-0087" title="">Characteristics of excluded studies</a>; <a href="./references#CD008205-sec-0088" title="">Characteristics of studies awaiting classification</a>. </p> <p>After performing the searches of the electronic databases of CENTRAL, MEDLINE (PubMed) and Embase (Ovid) (in June 2009), we identified 1703 references. Following initial screening of the titles and abstracts, or both, we excluded 1572 which clearly did not meet all prespecified criteria for this systematic review. We obtained 131 articles in full text, of which seven met all the inclusion criteria. For an Icelandic article, it was unclear if the study was eligible for inclusion. We are waiting for the translation. Therefore, this study was added to the <a href="./references#CD008205-sec-0088" title="">Characteristics of studies awaiting classification</a> table. The other 123 studies were not eligible for inclusion for the reasons described in the <a href="./references#CD008205-sec-0087" title="">Characteristics of excluded studies</a> table. </p> <p>After scanning the reference lists of relevant studies and reviews, 55 additional articles were retrieved for more detailed examination, of which 13 met all the inclusion criteria. Forty‐two studies were added to the <a href="./references#CD008205-sec-0087" title="">Characteristics of excluded studies</a> table. By scanning the conference proceedings of SIOP, we identified two eligible studies that have not been published yet and are waiting for further assessment (see the <a href="./references#CD008205-sec-0088" title="">Characteristics of studies awaiting classification</a> table). </p> <p>Running the searches for the update in CENTRAL, MEDLINE and Embase (in January 2018) yielded a total of 1875 new references (see <a href="#CD008205-fig-0001">Figure 1</a>). Following screening of the titles, abstracts, or both, we excluded 1804 which clearly did not meet the criteria for considering studies for this review. We obtained 71 articles in full text, of which 11 met all the inclusion criteria. In addition, the electronic search yielded one abstract of a conference proceeding. At the time of data extraction, this study was published and therefore included as well. The other 59 articles were excluded for reasons described in the <a href="./references#CD008205-sec-0087" title="">Characteristics of excluded studies</a> table. Scanning the reference lists of relevant studies and reviews, two articles were retrieved for detailed examination. One study met the inclusion criteria and one study did not meet the inclusion criteria and was added to the <a href="./references#CD008205-sec-0087" title="">Characteristics of excluded studies</a> table. By scanning the conference proceedings of SIOP and ASPHO, we identified three eligible studies that have not been published yet and are waiting for further assessment (see the <a href="./references#CD008205-sec-0088" title="">Characteristics of studies awaiting classification</a> table). </p> <div class="figure" id="CD008205-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD008205-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008205.pub3/media/CDSR/CD008205/image_n/nCD008205-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD008205-sec-0059"> <h4 class="title">Included studies</h4> <p>In total, our search identified 33 eligible studies examining the association between antineoplastic treatment for childhood cancer and hepatic late adverse effects. Characteristics of the included studies are summarised below and their baseline characteristics are described in the <a href="./references#CD008205-sec-0086" title="">Characteristics of included studies</a> table. It should be noted, however, that there might be partial overlap in included participants between the following studies: <a href="#CD008205-bbs2-0017">Locasciulli 1983</a>, <a href="#CD008205-bbs2-0018">Locasciulli 1985</a>, <a href="#CD008205-bbs2-0019">Locasciulli 1991a</a> and <a href="#CD008205-bbs2-0020">Locasciulli 1997a</a>; <a href="#CD008205-bbs2-0011">Guido 1991</a> and <a href="#CD008205-bbs2-0025">Rossetti 1991</a>; <a href="#CD008205-bbs2-0014">Hyodo 2012</a> and <a href="#CD008205-bbs2-0031">Tomita 2011</a>. </p> <p>The total number of participants included in the 33 identified cohort studies who received treatment with a high potential for hepatic late adverse effects was 7876, ranging from 19 to 2753 childhood cancer survivors per study. Sixteen studies included participants diagnosed with leukaemia (that is, acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML), and acute non‐lymphoblastic leukaemia (ANLL)) (<a href="#CD008205-bbs2-0001">Aricò 1994</a>; <a href="#CD008205-bbs2-0003">Bessho 1994</a>; <a href="#CD008205-bbs2-0005">Chotsampancharoen 2009</a>; <a href="#CD008205-bbs2-0006">Delvecchio 2017</a>; <a href="#CD008205-bbs2-0007">El‐Rashedy 2017</a>; <a href="#CD008205-bbs2-0011">Guido 1991</a>; <a href="#CD008205-bbs2-0017">Locasciulli 1983</a>; <a href="#CD008205-bbs2-0018">Locasciulli 1985</a>; <a href="#CD008205-bbs2-0019">Locasciulli 1991a</a>; <a href="#CD008205-bbs2-0020">Locasciulli 1997a</a>; <a href="#CD008205-bbs2-0022">Matsuzaki 2001</a>; <a href="#CD008205-bbs2-0024">Ratner 1986</a>; <a href="#CD008205-bbs2-0025">Rossetti 1991</a>; <a href="#CD008205-bbs2-0028">Skou 2014</a>; <a href="#CD008205-bbs2-0032">Vora 2006</a>; <a href="#CD008205-bbs2-0033">Weber 1987</a>); four studies included participants with various forms of leukaemia and non‐malignant disease (<a href="#CD008205-bbs2-0009">Frisk 1998</a>; <a href="#CD008205-bbs2-0014">Hyodo 2012</a>; <a href="#CD008205-bbs2-0020">Locasciulli 1997a</a>; <a href="#CD008205-bbs2-0031">Tomita 2011</a>); one study with Wilms' tumour, neuroblastoma and hepatoblastoma (<a href="#CD008205-bbs2-0030">Tefft 1970</a>); one study with hepatoblastoma (<a href="#CD008205-bbs2-0029">Stringer 1995</a>); one study with various forms of leukaemia, benign haematological diseases, immunological diseases, and other inborn errors (<a href="#CD008205-bbs2-0004">Bresters 2008</a>); one study with Wilms' tumour (<a href="#CD008205-bbs2-0015">Jagt 2009</a>); one study with neuroblastoma (<a href="#CD008205-bbs2-0008">French 2012</a>); and eight studies with various tumours (<a href="#CD008205-bbs2-0002">Ballauff 1999</a>; <a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0012">Gunn 2016</a>; <a href="#CD008205-bbs2-0013">Hudson 2013</a>; <a href="#CD008205-bbs2-0016">Landier 2012</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0026">Schempp 2016</a>; <a href="#CD008205-bbs2-0027">Seth 2017</a>). </p> <p>In 31 of the 33 studies, participants were treated with chemotherapy; in two studies, it was unclear whether the participants received chemotherapy (<a href="#CD008205-bbs2-0005">Chotsampancharoen 2009</a>; <a href="#CD008205-bbs2-0026">Schempp 2016</a>). In 24 studies, the type of chemotherapy was mentioned, which varied considerably across the studies (<a href="#CD008205-bbs2-0003">Bessho 1994</a>; <a href="#CD008205-bbs2-0004">Bresters 2008</a>; <a href="#CD008205-bbs2-0006">Delvecchio 2017</a>; <a href="#CD008205-bbs2-0007">El‐Rashedy 2017</a>; <a href="#CD008205-bbs2-0009">Frisk 1998</a>; <a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0011">Guido 1991</a>; <a href="#CD008205-bbs2-0013">Hudson 2013</a>; <a href="#CD008205-bbs2-0014">Hyodo 2012</a>; <a href="#CD008205-bbs2-0015">Jagt 2009</a>; <a href="#CD008205-bbs2-0016">Landier 2012</a>; <a href="#CD008205-bbs2-0017">Locasciulli 1983</a>; <a href="#CD008205-bbs2-0018">Locasciulli 1985</a>; <a href="#CD008205-bbs2-0021">Locasciulli 1997b</a>; <a href="#CD008205-bbs2-0022">Matsuzaki 2001</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0024">Ratner 1986</a>; <a href="#CD008205-bbs2-0025">Rossetti 1991</a>; <a href="#CD008205-bbs2-0028">Skou 2014</a>; <a href="#CD008205-bbs2-0029">Stringer 1995</a>; <a href="#CD008205-bbs2-0030">Tefft 1970</a>; <a href="#CD008205-bbs2-0031">Tomita 2011</a>; <a href="#CD008205-bbs2-0032">Vora 2006</a>; <a href="#CD008205-bbs2-0033">Weber 1987</a>). Nine studies mentioned the chemotherapy dose according to the treatment protocol, which varied widely (<a href="#CD008205-bbs2-0003">Bessho 1994</a>; <a href="#CD008205-bbs2-0013">Hudson 2013</a>; <a href="#CD008205-bbs2-0015">Jagt 2009</a>; <a href="#CD008205-bbs2-0016">Landier 2012</a>; <a href="#CD008205-bbs2-0021">Locasciulli 1997b</a>; <a href="#CD008205-bbs2-0022">Matsuzaki 2001</a>; <a href="#CD008205-bbs2-0029">Stringer 1995</a>; <a href="#CD008205-bbs2-0032">Vora 2006</a>; <a href="#CD008205-bbs2-0033">Weber 1987</a>). Four studies reported the dose actually received by the participants (<a href="#CD008205-bbs2-0003">Bessho 1994</a>; <a href="#CD008205-bbs2-0013">Hudson 2013</a>; <a href="#CD008205-bbs2-0016">Landier 2012</a>; <a href="#CD008205-bbs2-0028">Skou 2014</a>). Eighteen of the 33 studies reported whether the participants were treated with radiotherapy involving the liver (<a href="#CD008205-bbs2-0004">Bresters 2008</a>; <a href="#CD008205-bbs2-0005">Chotsampancharoen 2009</a>; <a href="#CD008205-bbs2-0006">Delvecchio 2017</a>; <a href="#CD008205-bbs2-0007">El‐Rashedy 2017</a>; <a href="#CD008205-bbs2-0008">French 2012</a>; <a href="#CD008205-bbs2-0009">Frisk 1998</a>; <a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0012">Gunn 2016</a>; <a href="#CD008205-bbs2-0013">Hudson 2013</a>; <a href="#CD008205-bbs2-0014">Hyodo 2012</a>; <a href="#CD008205-bbs2-0016">Landier 2012</a>; <a href="#CD008205-bbs2-0021">Locasciulli 1997b</a>; <a href="#CD008205-bbs2-0022">Matsuzaki 2001</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0028">Skou 2014</a>; <a href="#CD008205-bbs2-0029">Stringer 1995</a>; <a href="#CD008205-bbs2-0030">Tefft 1970</a>; <a href="#CD008205-bbs2-0031">Tomita 2011</a>), of which fourteen studies included participants who received radiotherapy involving the liver (<a href="#CD008205-bbs2-0004">Bresters 2008</a>; <a href="#CD008205-bbs2-0005">Chotsampancharoen 2009</a>; <a href="#CD008205-bbs2-0008">French 2012</a>; <a href="#CD008205-bbs2-0009">Frisk 1998</a>; <a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0012">Gunn 2016</a>; <a href="#CD008205-bbs2-0013">Hudson 2013</a>; <a href="#CD008205-bbs2-0014">Hyodo 2012</a>; <a href="#CD008205-bbs2-0016">Landier 2012</a>; <a href="#CD008205-bbs2-0021">Locasciulli 1997b</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0029">Stringer 1995</a>; <a href="#CD008205-bbs2-0030">Tefft 1970</a>; <a href="#CD008205-bbs2-0031">Tomita 2011</a>). Fourteen studies mentioned the radiotherapy field and dose, which varied from 5.0 to 14.4 Gy TBI (<a href="#CD008205-bbs2-0005">Chotsampancharoen 2009</a>; <a href="#CD008205-bbs2-0008">French 2012</a>; <a href="#CD008205-bbs2-0009">Frisk 1998</a>; <a href="#CD008205-bbs2-0014">Hyodo 2012</a>; <a href="#CD008205-bbs2-0021">Locasciulli 1997b</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0031">Tomita 2011</a>); 3.0 to 76.0 Gy (thoraco‐)abdominal irradiation (<a href="#CD008205-bbs2-0008">French 2012</a>; <a href="#CD008205-bbs2-0013">Hudson 2013</a>; <a href="#CD008205-bbs2-0014">Hyodo 2012</a>; <a href="#CD008205-bbs2-0016">Landier 2012</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0031">Tomita 2011</a>); and less than 25 Gy to more than 35 Gy liver irradiation (<a href="#CD008205-bbs2-0030">Tefft 1970</a>). One study calculated the volumetric dose to the liver and reported that the median percentage of liver that received 10 Gy was 51.4%, the median percentage of liver that received 15 Gy was 34.6% and the median percentage of liver that received 20 Gy was 25.3% (<a href="#CD008205-bbs2-0010">Green 2019</a>). Four studies included participants treated with a hepatectomy (<a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0029">Stringer 1995</a>; <a href="#CD008205-bbs2-0030">Tefft 1970</a>). Moreover, fifteen studies included participants treated with BMT (<a href="#CD008205-bbs2-0004">Bresters 2008</a>; <a href="#CD008205-bbs2-0005">Chotsampancharoen 2009</a>; <a href="#CD008205-bbs2-0008">French 2012</a>; <a href="#CD008205-bbs2-0009">Frisk 1998</a>; <a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0012">Gunn 2016</a>; <a href="#CD008205-bbs2-0013">Hudson 2013</a>; <a href="#CD008205-bbs2-0014">Hyodo 2012</a>; <a href="#CD008205-bbs2-0016">Landier 2012</a>; <a href="#CD008205-bbs2-0019">Locasciulli 1991a</a>; <a href="#CD008205-bbs2-0021">Locasciulli 1997b</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0026">Schempp 2016</a>; <a href="#CD008205-bbs2-0028">Skou 2014</a>; <a href="#CD008205-bbs2-0031">Tomita 2011</a>). </p> <p>Twenty‐four studies mentioned the age at diagnosis. Within studies reporting mean or median values, the mean/median age ranged from 0.2 to 10.2 years (<a href="#CD008205-bbs2-0003">Bessho 1994</a>; <a href="#CD008205-bbs2-0006">Delvecchio 2017</a>; <a href="#CD008205-bbs2-0007">El‐Rashedy 2017</a>; <a href="#CD008205-bbs2-0008">French 2012</a>; <a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0011">Guido 1991</a>; <a href="#CD008205-bbs2-0012">Gunn 2016</a>; <a href="#CD008205-bbs2-0013">Hudson 2013</a>; <a href="#CD008205-bbs2-0014">Hyodo 2012</a>; <a href="#CD008205-bbs2-0015">Jagt 2009</a>; <a href="#CD008205-bbs2-0016">Landier 2012</a>; <a href="#CD008205-bbs2-0017">Locasciulli 1983</a>; <a href="#CD008205-bbs2-0018">Locasciulli 1985</a>; <a href="#CD008205-bbs2-0019">Locasciulli 1991a</a>; <a href="#CD008205-bbs2-0020">Locasciulli 1997a</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0026">Schempp 2016</a>; <a href="#CD008205-bbs2-0027">Seth 2017</a>; <a href="#CD008205-bbs2-0028">Skou 2014</a>; <a href="#CD008205-bbs2-0029">Stringer 1995</a>; <a href="#CD008205-bbs2-0030">Tefft 1970</a>; <a href="#CD008205-bbs2-0031">Tomita 2011</a>; <a href="#CD008205-bbs2-0032">Vora 2006</a>; <a href="#CD008205-bbs2-0033">Weber 1987</a>). The age at follow‐up was reported by seventeen studies (<a href="#CD008205-bbs2-0001">Aricò 1994</a>; <a href="#CD008205-bbs2-0002">Ballauff 1999</a>; <a href="#CD008205-bbs2-0003">Bessho 1994</a>; <a href="#CD008205-bbs2-0006">Delvecchio 2017</a>; <a href="#CD008205-bbs2-0007">El‐Rashedy 2017</a>; <a href="#CD008205-bbs2-0008">French 2012</a>; <a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0012">Gunn 2016</a>; <a href="#CD008205-bbs2-0013">Hudson 2013</a>; <a href="#CD008205-bbs2-0014">Hyodo 2012</a>; <a href="#CD008205-bbs2-0016">Landier 2012</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0025">Rossetti 1991</a>; <a href="#CD008205-bbs2-0026">Schempp 2016</a>; <a href="#CD008205-bbs2-0027">Seth 2017</a>; <a href="#CD008205-bbs2-0028">Skou 2014</a>; <a href="#CD008205-bbs2-0031">Tomita 2011</a>) and ranged from a mean/median 9.7 to 32.0 years in studies that reported mean or median values. All but four studies (<a href="#CD008205-bbs2-0012">Gunn 2016</a>; <a href="#CD008205-bbs2-0024">Ratner 1986</a>; <a href="#CD008205-bbs2-0008">French 2012</a>; <a href="#CD008205-bbs2-0032">Vora 2006</a>) mentioned the gender of the included participants. The percentage of females in these studies varied between 0% and 64%. For the 31 studies that reported follow‐up duration, the reported mean or median duration varied widely from 2.0 years after the end of treatment to 25.1 years since primary cancer diagnosis (<a href="#CD008205-bbs2-0001">Aricò 1994</a>; <a href="#CD008205-bbs2-0002">Ballauff 1999</a>; <a href="#CD008205-bbs2-0003">Bessho 1994</a>; <a href="#CD008205-bbs2-0004">Bresters 2008</a>; <a href="#CD008205-bbs2-0005">Chotsampancharoen 2009</a>; <a href="#CD008205-bbs2-0006">Delvecchio 2017</a>; <a href="#CD008205-bbs2-0007">El‐Rashedy 2017</a>; <a href="#CD008205-bbs2-0008">French 2012</a>; <a href="#CD008205-bbs2-0009">Frisk 1998</a>; <a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0011">Guido 1991</a>; <a href="#CD008205-bbs2-0012">Gunn 2016</a>; <a href="#CD008205-bbs2-0013">Hudson 2013</a>; <a href="#CD008205-bbs2-0014">Hyodo 2012</a>; <a href="#CD008205-bbs2-0016">Landier 2012</a>; <a href="#CD008205-bbs2-0017">Locasciulli 1983</a>; <a href="#CD008205-bbs2-0018">Locasciulli 1985</a>; <a href="#CD008205-bbs2-0019">Locasciulli 1991a</a>; <a href="#CD008205-bbs2-0020">Locasciulli 1997a</a>; <a href="#CD008205-bbs2-0021">Locasciulli 1997b</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0024">Ratner 1986</a>; <a href="#CD008205-bbs2-0025">Rossetti 1991</a>; <a href="#CD008205-bbs2-0026">Schempp 2016</a>; <a href="#CD008205-bbs2-0027">Seth 2017</a>; <a href="#CD008205-bbs2-0029">Stringer 1995</a>; <a href="#CD008205-bbs2-0028">Skou 2014</a>; <a href="#CD008205-bbs2-0030">Tefft 1970</a>; <a href="#CD008205-bbs2-0031">Tomita 2011</a>; <a href="#CD008205-bbs2-0032">Vora 2006</a>; <a href="#CD008205-bbs2-0033">Weber 1987</a>). </p> <p>In the included studies, hepatic late adverse effects were variably defined using ALT, AST, γGT, ALP, bilirubin, and PTT. Fourteen studies defined hepatic late adverse effects by abnormal values of serum ALT or AST, or both (<a href="#CD008205-bbs2-0001">Aricò 1994</a>; <a href="#CD008205-bbs2-0003">Bessho 1994</a>; <a href="#CD008205-bbs2-0004">Bresters 2008</a>; <a href="#CD008205-bbs2-0011">Guido 1991</a>; <a href="#CD008205-bbs2-0012">Gunn 2016</a>; <a href="#CD008205-bbs2-0017">Locasciulli 1983</a>; <a href="#CD008205-bbs2-0018">Locasciulli 1985</a>; <a href="#CD008205-bbs2-0019">Locasciulli 1991a</a>; <a href="#CD008205-bbs2-0020">Locasciulli 1997a</a>; <a href="#CD008205-bbs2-0021">Locasciulli 1997b</a>; <a href="#CD008205-bbs2-0022">Matsuzaki 2001</a>; <a href="#CD008205-bbs2-0024">Ratner 1986</a>; <a href="#CD008205-bbs2-0025">Rossetti 1991</a>; <a href="#CD008205-bbs2-0032">Vora 2006</a>); eight studies defined hepatic late adverse effects by describing separate abnormal values of ALT, AST ALP, bilirubin prothrombin ratio or albumin (<a href="#CD008205-bbs2-0005">Chotsampancharoen 2009</a>; <a href="#CD008205-bbs2-0006">Delvecchio 2017</a>; <a href="#CD008205-bbs2-0007">El‐Rashedy 2017</a>; <a href="#CD008205-bbs2-0008">French 2012</a>; <a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0016">Landier 2012</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0028">Skou 2014</a>); nine studies defined hepatic late adverse effects by combined measurements of ALT, AST, bilirubin, γGT, ALP and/or PTT (<a href="#CD008205-bbs2-0002">Ballauff 1999</a>; <a href="#CD008205-bbs2-0009">Frisk 1998</a>; <a href="#CD008205-bbs2-0013">Hudson 2013</a>; <a href="#CD008205-bbs2-0014">Hyodo 2012</a>; <a href="#CD008205-bbs2-0015">Jagt 2009</a>; <a href="#CD008205-bbs2-0026">Schempp 2016</a>; <a href="#CD008205-bbs2-0030">Tefft 1970</a>; <a href="#CD008205-bbs2-0031">Tomita 2011</a>; <a href="#CD008205-bbs2-0033">Weber 1987</a>); and for two studies, it was unclear which biochemical liver function tests were used (<a href="#CD008205-bbs2-0027">Seth 2017</a>; <a href="#CD008205-bbs2-0029">Stringer 1995</a>). In 19 studies, the upper limits of normal were described (<a href="#CD008205-bbs2-0001">Aricò 1994</a>; <a href="#CD008205-bbs2-0002">Ballauff 1999</a>; <a href="#CD008205-bbs2-0003">Bessho 1994</a>; <a href="#CD008205-bbs2-0004">Bresters 2008</a>; <a href="#CD008205-bbs2-0008">French 2012</a>; <a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0013">Hudson 2013</a>; <a href="#CD008205-bbs2-0015">Jagt 2009</a>; <a href="#CD008205-bbs2-0016">Landier 2012</a>; <a href="#CD008205-bbs2-0017">Locasciulli 1983</a>; <a href="#CD008205-bbs2-0018">Locasciulli 1985</a>; <a href="#CD008205-bbs2-0019">Locasciulli 1991a</a>; <a href="#CD008205-bbs2-0020">Locasciulli 1997a</a>; <a href="#CD008205-bbs2-0021">Locasciulli 1997b</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0024">Ratner 1986</a>; <a href="#CD008205-bbs2-0025">Rossetti 1991</a>; <a href="#CD008205-bbs2-0028">Skou 2014</a>; <a href="#CD008205-bbs2-0033">Weber 1987</a>). Ten studies defined hepatic late adverse effects as ALT and/or AST above the upper limit of normal (<a href="#CD008205-bbs2-0001">Aricò 1994</a>; <a href="#CD008205-bbs2-0003">Bessho 1994</a>; <a href="#CD008205-bbs2-0004">Bresters 2008</a>; <a href="#CD008205-bbs2-0008">French 2012</a>; <a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0019">Locasciulli 1991a</a>; <a href="#CD008205-bbs2-0020">Locasciulli 1997a</a>; <a href="#CD008205-bbs2-0021">Locasciulli 1997b</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0028">Skou 2014</a>); five studies as ALT and/or AST above two times the upper limit of normal (<a href="#CD008205-bbs2-0004">Bresters 2008</a>; <a href="#CD008205-bbs2-0016">Landier 2012</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0024">Ratner 1986</a>; <a href="#CD008205-bbs2-0025">Rossetti 1991</a>); two studies as ALT or AST, or both, above three times the upper limit of normal (<a href="#CD008205-bbs2-0017">Locasciulli 1983</a>; <a href="#CD008205-bbs2-0018">Locasciulli 1985</a>); two studies as ALP above the upper limit of normal (<a href="#CD008205-bbs2-0008">French 2012</a>; <a href="#CD008205-bbs2-0028">Skou 2014</a>); three studies as bilirubin above the upper limit of normal (<a href="#CD008205-bbs2-0008">French 2012</a>; <a href="#CD008205-bbs2-0016">Landier 2012</a>; <a href="#CD008205-bbs2-0028">Skou 2014</a>); one study as γGT above and two times above the upper limit of normal (<a href="#CD008205-bbs2-0023">Mulder 2013</a>); and four studies as combinations of ALT, AST, bilirubin, γGT and/or ALP above the upper limit of normal (<a href="#CD008205-bbs2-0002">Ballauff 1999</a>; <a href="#CD008205-bbs2-0013">Hudson 2013</a>; <a href="#CD008205-bbs2-0015">Jagt 2009</a>; <a href="#CD008205-bbs2-0016">Landier 2012</a>; <a href="#CD008205-bbs2-0033">Weber 1987</a>). In four studies, liver biopsies were performed in a selected group of participants (<a href="#CD008205-bbs2-0020">Locasciulli 1997a</a>; <a href="#CD008205-bbs2-0024">Ratner 1986</a>; <a href="#CD008205-bbs2-0031">Tomita 2011</a>; <a href="#CD008205-bbs2-0032">Vora 2006</a>). </p> </section> </section> <section id="CD008205-sec-0060"> <h3 class="title">Risk of bias in included studies</h3> <p>Data on the risk of bias in the 33 cohort studies are described in the <a href="./references#CD008205-sec-0086" title="">Characteristics of included studies</a> table and are shown in <a href="#CD008205-fig-0002">Figure 2</a> and <a href="#CD008205-fig-0003">Figure 3</a>. All studies were found to have methodological limitations. </p> <div class="figure" id="CD008205-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008205-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008205.pub3/media/CDSR/CD008205/image_n/nCD008205-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD008205-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008205-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008205.pub3/media/CDSR/CD008205/image_n/nCD008205-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <p>For evaluation of internal validity, we assessed the risk of selection bias, attrition bias, detection bias, and confounding present in the included studies. </p> <p>In five of the 33 studies, the described study group consisted of the entire original cohort of childhood cancer survivors (<a href="#CD008205-bbs2-0001">Aricò 1994</a>; <a href="#CD008205-bbs2-0002">Ballauff 1999</a>; <a href="#CD008205-bbs2-0009">Frisk 1998</a>; <a href="#CD008205-bbs2-0021">Locasciulli 1997b</a>; <a href="#CD008205-bbs2-0029">Stringer 1995</a>). Nine studies described a subgroup of the original cohort (<a href="#CD008205-bbs2-0004">Bresters 2008</a>; <a href="#CD008205-bbs2-0005">Chotsampancharoen 2009</a>; <a href="#CD008205-bbs2-0008">French 2012</a>; <a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0013">Hudson 2013</a>; <a href="#CD008205-bbs2-0019">Locasciulli 1991a</a>; <a href="#CD008205-bbs2-0020">Locasciulli 1997a</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0028">Skou 2014</a>). In one study, this subgroup consisted of more than 90% of the original cohort (<a href="#CD008205-bbs2-0020">Locasciulli 1997a</a>). In the other eight studies, this subgroup neither consisted of more than 90% of the original cohort nor was it a random sample with respect to the cancer treatment (<a href="#CD008205-bbs2-0004">Bresters 2008</a>; <a href="#CD008205-bbs2-0005">Chotsampancharoen 2009</a>; <a href="#CD008205-bbs2-0008">French 2012</a>; <a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0013">Hudson 2013</a>; <a href="#CD008205-bbs2-0019">Locasciulli 1991a</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0028">Skou 2014</a>). For 19 studies, the number of participants in the original cohort was not mentioned (<a href="#CD008205-bbs2-0003">Bessho 1994</a>; <a href="#CD008205-bbs2-0006">Delvecchio 2017</a>; <a href="#CD008205-bbs2-0007">El‐Rashedy 2017</a>; <a href="#CD008205-bbs2-0011">Guido 1991</a>; <a href="#CD008205-bbs2-0012">Gunn 2016</a>; <a href="#CD008205-bbs2-0014">Hyodo 2012</a>; <a href="#CD008205-bbs2-0015">Jagt 2009</a>; <a href="#CD008205-bbs2-0016">Landier 2012</a>; <a href="#CD008205-bbs2-0017">Locasciulli 1983</a>; <a href="#CD008205-bbs2-0018">Locasciulli 1985</a>; <a href="#CD008205-bbs2-0022">Matsuzaki 2001</a>; <a href="#CD008205-bbs2-0024">Ratner 1986</a>; <a href="#CD008205-bbs2-0025">Rossetti 1991</a>; <a href="#CD008205-bbs2-0026">Schempp 2016</a>; <a href="#CD008205-bbs2-0027">Seth 2017</a>; <a href="#CD008205-bbs2-0030">Tefft 1970</a>; <a href="#CD008205-bbs2-0031">Tomita 2011</a>; <a href="#CD008205-bbs2-0032">Vora 2006</a>; <a href="#CD008205-bbs2-0033">Weber 1987</a>). For these studies, it was unclear whether the described study group consisted of more than 90% of the original cohort of childhood cancer survivors or whether it was a random sample with respect to the cancer treatment. Hence, in six of the 33 studies (18.2%) the study group was representative. So, selection bias could not be ruled out in 81.8% of the included studies. </p> <p>Twenty‐eight studies (84.8%) had an adequate follow‐up (based on &gt; 60% of the study group of interest) (<a href="#CD008205-bbs2-0001">Aricò 1994</a>; <a href="#CD008205-bbs2-0002">Ballauff 1999</a>; <a href="#CD008205-bbs2-0003">Bessho 1994</a>; <a href="#CD008205-bbs2-0004">Bresters 2008</a>; <a href="#CD008205-bbs2-0006">Delvecchio 2017</a>; <a href="#CD008205-bbs2-0007">El‐Rashedy 2017</a>; <a href="#CD008205-bbs2-0008">French 2012</a>; <a href="#CD008205-bbs2-0009">Frisk 1998</a>; <a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0012">Gunn 2016</a>; <a href="#CD008205-bbs2-0013">Hudson 2013</a>; <a href="#CD008205-bbs2-0014">Hyodo 2012</a>; <a href="#CD008205-bbs2-0015">Jagt 2009</a>; <a href="#CD008205-bbs2-0016">Landier 2012</a>; <a href="#CD008205-bbs2-0017">Locasciulli 1983</a>; <a href="#CD008205-bbs2-0019">Locasciulli 1991a</a>; <a href="#CD008205-bbs2-0020">Locasciulli 1997a</a>; <a href="#CD008205-bbs2-0021">Locasciulli 1997b</a>; <a href="#CD008205-bbs2-0022">Matsuzaki 2001</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0024">Ratner 1986</a>; <a href="#CD008205-bbs2-0025">Rossetti 1991</a>; <a href="#CD008205-bbs2-0028">Skou 2014</a>; <a href="#CD008205-bbs2-0029">Stringer 1995</a>; <a href="#CD008205-bbs2-0030">Tefft 1970</a>; <a href="#CD008205-bbs2-0031">Tomita 2011</a>; <a href="#CD008205-bbs2-0032">Vora 2006</a>; <a href="#CD008205-bbs2-0033">Weber 1987</a>), of which 22 studies assessed the outcome for more than 90% of the study group of interest (<a href="#CD008205-bbs2-0001">Aricò 1994</a>; <a href="#CD008205-bbs2-0002">Ballauff 1999</a>; <a href="#CD008205-bbs2-0003">Bessho 1994</a>; <a href="#CD008205-bbs2-0004">Bresters 2008</a>; <a href="#CD008205-bbs2-0006">Delvecchio 2017</a>; <a href="#CD008205-bbs2-0007">El‐Rashedy 2017</a>; <a href="#CD008205-bbs2-0009">Frisk 1998</a>; <a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0012">Gunn 2016</a>; <a href="#CD008205-bbs2-0013">Hudson 2013</a>; <a href="#CD008205-bbs2-0014">Hyodo 2012</a>; <a href="#CD008205-bbs2-0016">Landier 2012</a>; <a href="#CD008205-bbs2-0019">Locasciulli 1991a</a>; <a href="#CD008205-bbs2-0020">Locasciulli 1997a</a>; <a href="#CD008205-bbs2-0021">Locasciulli 1997b</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0024">Ratner 1986</a>; <a href="#CD008205-bbs2-0028">Skou 2014</a>; <a href="#CD008205-bbs2-0029">Stringer 1995</a>; <a href="#CD008205-bbs2-0031">Tomita 2011</a>; <a href="#CD008205-bbs2-0032">Vora 2006</a>; <a href="#CD008205-bbs2-0033">Weber 1987</a>). Two studies assessed the outcome for less than 60% of the study group of interest and thus were scored as having incomplete follow‐up (<a href="#CD008205-bbs2-0011">Guido 1991</a>; <a href="#CD008205-bbs2-0018">Locasciulli 1985</a>), and, for three studies, the completion of follow‐up was unclear (<a href="#CD008205-bbs2-0005">Chotsampancharoen 2009</a>; <a href="#CD008205-bbs2-0026">Schempp 2016</a>; <a href="#CD008205-bbs2-0026">Schempp 2016</a>). Hence, there was a risk of attrition bias in five of the 33 studies (15.2%) </p> <p>In all studies, liver enzymes were biochemically measured. This outcome is not likely to be influenced by lack of blinding. In four studies that performed liver biopsies, it was unclear if the outcome assessors were blinded (<a href="#CD008205-bbs2-0020">Locasciulli 1997a</a>; <a href="#CD008205-bbs2-0024">Ratner 1986</a>; <a href="#CD008205-bbs2-0031">Tomita 2011</a>; <a href="#CD008205-bbs2-0032">Vora 2006</a>). </p> <p>Eighteen studies assessed possible risk factors for the development of hepatic late adverse effects (<a href="#CD008205-bbs2-0001">Aricò 1994</a>; <a href="#CD008205-bbs2-0002">Ballauff 1999</a>; <a href="#CD008205-bbs2-0004">Bresters 2008</a>; <a href="#CD008205-bbs2-0005">Chotsampancharoen 2009</a>; <a href="#CD008205-bbs2-0006">Delvecchio 2017</a>; <a href="#CD008205-bbs2-0007">El‐Rashedy 2017</a>; <a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0012">Gunn 2016</a>; <a href="#CD008205-bbs2-0013">Hudson 2013</a>; <a href="#CD008205-bbs2-0014">Hyodo 2012</a>; <a href="#CD008205-bbs2-0017">Locasciulli 1983</a>; <a href="#CD008205-bbs2-0019">Locasciulli 1991a</a>; <a href="#CD008205-bbs2-0020">Locasciulli 1997a</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0025">Rossetti 1991</a>; <a href="#CD008205-bbs2-0026">Schempp 2016</a>; <a href="#CD008205-bbs2-0030">Tefft 1970</a>; <a href="#CD008205-bbs2-0031">Tomita 2011</a>). Only two out of these 18 studies (<a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>) conducted multivariable analyses with adjustment for important confounders. So, there was a risk of confounding in 88.9% of the studies which assessed possible risk factors. </p> <p>For evaluation of external validity, we assessed the risk of reporting bias present in the included studies. </p> <p>In 18 of the 33 studies (54.5%), the study group was well‐defined in terms of antineoplastic therapy exposure and chronic viral hepatitis (<a href="#CD008205-bbs2-0003">Bessho 1994</a>; <a href="#CD008205-bbs2-0004">Bresters 2008</a>;<a href="#CD008205-bbs2-0007">El‐Rashedy 2017</a>; <a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0009">Frisk 1998</a>; <a href="#CD008205-bbs2-0011">Guido 1991</a>; <a href="#CD008205-bbs2-0013">Hudson 2013</a>; <a href="#CD008205-bbs2-0014">Hyodo 2012</a>; <a href="#CD008205-bbs2-0016">Landier 2012</a>; <a href="#CD008205-bbs2-0017">Locasciulli 1983</a>; <a href="#CD008205-bbs2-0018">Locasciulli 1985</a>; <a href="#CD008205-bbs2-0021">Locasciulli 1997b</a>; <a href="#CD008205-bbs2-0022">Matsuzaki 2001</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0028">Skou 2014</a>; <a href="#CD008205-bbs2-0024">Ratner 1986</a>; <a href="#CD008205-bbs2-0025">Rossetti 1991</a>; <a href="#CD008205-bbs2-0031">Tomita 2011</a>). The other 15 studies failed to mention the type of chemotherapy (<a href="#CD008205-bbs2-0001">Aricò 1994</a>; <a href="#CD008205-bbs2-0002">Ballauff 1999</a>; <a href="#CD008205-bbs2-0008">French 2012</a>; <a href="#CD008205-bbs2-0012">Gunn 2016</a>; <a href="#CD008205-bbs2-0019">Locasciulli 1991a</a>; <a href="#CD008205-bbs2-0020">Locasciulli 1997a</a>; <a href="#CD008205-bbs2-0026">Schempp 2016</a>; <a href="#CD008205-bbs2-0027">Seth 2017</a>) or the number of participants with chronic viral hepatitis (<a href="#CD008205-bbs2-0005">Chotsampancharoen 2009</a>; <a href="#CD008205-bbs2-0006">Delvecchio 2017</a>; <a href="#CD008205-bbs2-0012">Gunn 2016</a>; <a href="#CD008205-bbs2-0015">Jagt 2009</a>; <a href="#CD008205-bbs2-0026">Schempp 2016</a>; <a href="#CD008205-bbs2-0029">Stringer 1995</a>; <a href="#CD008205-bbs2-0030">Tefft 1970</a>; <a href="#CD008205-bbs2-0032">Vora 2006</a>; <a href="#CD008205-bbs2-0033">Weber 1987</a>). </p> <p>Twenty‐eight studies (84.8%) reported the length of follow‐up and therefore had a well‐defined follow‐up (<a href="#CD008205-bbs2-0001">Aricò 1994</a>; <a href="#CD008205-bbs2-0002">Ballauff 1999</a>; <a href="#CD008205-bbs2-0003">Bessho 1994</a>; <a href="#CD008205-bbs2-0004">Bresters 2008</a>; <a href="#CD008205-bbs2-0005">Chotsampancharoen 2009</a>; <a href="#CD008205-bbs2-0008">French 2012</a>; <a href="#CD008205-bbs2-0009">Frisk 1998</a>; <a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0011">Guido 1991</a>; <a href="#CD008205-bbs2-0013">Hudson 2013</a>; <a href="#CD008205-bbs2-0014">Hyodo 2012</a>; <a href="#CD008205-bbs2-0016">Landier 2012</a>; <a href="#CD008205-bbs2-0017">Locasciulli 1983</a>; <a href="#CD008205-bbs2-0018">Locasciulli 1985</a>; <a href="#CD008205-bbs2-0019">Locasciulli 1991a</a>; <a href="#CD008205-bbs2-0020">Locasciulli 1997a</a>; <a href="#CD008205-bbs2-0021">Locasciulli 1997b</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0024">Ratner 1986</a>; <a href="#CD008205-bbs2-0025">Rossetti 1991</a>; <a href="#CD008205-bbs2-0026">Schempp 2016</a>; <a href="#CD008205-bbs2-0027">Seth 2017</a>; <a href="#CD008205-bbs2-0028">Skou 2014</a>; <a href="#CD008205-bbs2-0029">Stringer 1995</a>; <a href="#CD008205-bbs2-0030">Tefft 1970</a>; <a href="#CD008205-bbs2-0031">Tomita 2011</a>; <a href="#CD008205-bbs2-0032">Vora 2006</a>; <a href="#CD008205-bbs2-0033">Weber 1987</a>). </p> <p>In 19 studies, the upper limits of normal for the liver function tests that were used were described (<a href="#CD008205-bbs2-0001">Aricò 1994</a>; <a href="#CD008205-bbs2-0002">Ballauff 1999</a>; <a href="#CD008205-bbs2-0003">Bessho 1994</a>; <a href="#CD008205-bbs2-0004">Bresters 2008</a>; <a href="#CD008205-bbs2-0008">French 2012</a>; <a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0013">Hudson 2013</a>; <a href="#CD008205-bbs2-0015">Jagt 2009</a>; <a href="#CD008205-bbs2-0016">Landier 2012</a>; <a href="#CD008205-bbs2-0017">Locasciulli 1983</a>; <a href="#CD008205-bbs2-0018">Locasciulli 1985</a>; <a href="#CD008205-bbs2-0019">Locasciulli 1991a</a>; <a href="#CD008205-bbs2-0020">Locasciulli 1997a</a>; <a href="#CD008205-bbs2-0021">Locasciulli 1997b</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0028">Skou 2014</a>; <a href="#CD008205-bbs2-0024">Ratner 1986</a>; <a href="#CD008205-bbs2-0025">Rossetti 1991</a>; <a href="#CD008205-bbs2-0033">Weber 1987</a>). The other studies did not mention the upper limits of normal. So 19 of the 33 studies (57.6%) had a well‐defined outcome. </p> <p>Eighteen studies assessed possible risk factors for the development of hepatic late adverse effects, of which all but one had a well‐defined risk estimation (94.4%) (<a href="#CD008205-bbs2-0001">Aricò 1994</a>; <a href="#CD008205-bbs2-0002">Ballauff 1999</a>; <a href="#CD008205-bbs2-0004">Bresters 2008</a>; <a href="#CD008205-bbs2-0005">Chotsampancharoen 2009</a>; <a href="#CD008205-bbs2-0006">Delvecchio 2017</a>; <a href="#CD008205-bbs2-0007">El‐Rashedy 2017</a>; <a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0012">Gunn 2016</a>; <a href="#CD008205-bbs2-0013">Hudson 2013</a>; <a href="#CD008205-bbs2-0014">Hyodo 2012</a>; <a href="#CD008205-bbs2-0017">Locasciulli 1983</a>; <a href="#CD008205-bbs2-0019">Locasciulli 1991a</a>; <a href="#CD008205-bbs2-0020">Locasciulli 1997a</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0025">Rossetti 1991</a>; <a href="#CD008205-bbs2-0030">Tefft 1970</a>; <a href="#CD008205-bbs2-0031">Tomita 2011</a>). </p> <p>Hence, reporting bias could not be ruled out in up to 63.6% of the included studies.</p> </section> <section id="CD008205-sec-0061"> <h3 class="title" id="CD008205-sec-0061">Effects of interventions</h3> <section id="CD008205-sec-0062"> <h4 class="title">Prevalence of hepatic late adverse effects</h4> <p>The prevalence of hepatic late adverse effects as measured by liver enzymes, bilirubin, or coagulation times was reported in all but three studies (<a href="#CD008205-bbs2-0005">Chotsampancharoen 2009</a>; <a href="#CD008205-bbs2-0006">Delvecchio 2017</a>; <a href="#CD008205-bbs2-0007">El‐Rashedy 2017</a>) and varied widely between 0% and 84.2% (see <a href="./references#CD008205-sec-0086" title="">Characteristics of included studies</a>). However, five studies estimated the prevalence of hepatic late adverse effects in a selected group of participants who were diagnosed with abnormal liver function during or soon after the cancer treatment (<a href="#CD008205-bbs2-0011">Guido 1991</a>; <a href="#CD008205-bbs2-0017">Locasciulli 1983</a>; <a href="#CD008205-bbs2-0018">Locasciulli 1985</a>; <a href="#CD008205-bbs2-0019">Locasciulli 1991a</a>; <a href="#CD008205-bbs2-0032">Vora 2006</a>). Excluding these studies resulted in a reported prevalence of 0% to 58.0%. </p> <p>Furthermore, hepatic late adverse effects were defined using different liver function tests with varying cut‐off limits. When selecting studies with a well‐defined outcome, that is, if the upper limits of normal for the liver function tests were described in the definition of hepatic late adverse effects, 19 studies remained (<a href="#CD008205-bbs2-0001">Aricò 1994</a>; <a href="#CD008205-bbs2-0002">Ballauff 1999</a>; <a href="#CD008205-bbs2-0003">Bessho 1994</a>; <a href="#CD008205-bbs2-0004">Bresters 2008</a>; <a href="#CD008205-bbs2-0008">French 2012</a>; <a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0013">Hudson 2013</a>; <a href="#CD008205-bbs2-0015">Jagt 2009</a>; <a href="#CD008205-bbs2-0016">Landier 2012</a>; <a href="#CD008205-bbs2-0017">Locasciulli 1983</a>; <a href="#CD008205-bbs2-0018">Locasciulli 1985</a>; <a href="#CD008205-bbs2-0019">Locasciulli 1991a</a>; <a href="#CD008205-bbs2-0020">Locasciulli 1997a</a>; <a href="#CD008205-bbs2-0021">Locasciulli 1997b</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0024">Ratner 1986</a>; <a href="#CD008205-bbs2-0025">Rossetti 1991</a>; <a href="#CD008205-bbs2-0028">Skou 2014</a>; <a href="#CD008205-bbs2-0033">Weber 1987</a>). </p> <section id="CD008205-sec-0063"> <h5 class="title">Cellular liver injury: ALT and AST</h5> <p>Eight studies defined hepatic late adverse effects as ALT above the upper limit of normal with prevalences ranging from 5.8% to 52.8% (<a href="#CD008205-bbs2-0001">Aricò 1994</a>; <a href="#CD008205-bbs2-0003">Bessho 1994</a>; <a href="#CD008205-bbs2-0008">French 2012</a>; <a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0020">Locasciulli 1997a</a>; <a href="#CD008205-bbs2-0021">Locasciulli 1997b</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0028">Skou 2014</a>) (<a href="#CD008205-tbl-0002">Table 2</a>). Two studies defined hepatic late adverse effects as AST above the upper limit of normal with a prevalence of 1.1% and 13.0%, respectively (<a href="#CD008205-bbs2-0028">Skou 2014</a>; <a href="#CD008205-bbs2-0008">French 2012</a>) (<a href="#CD008205-tbl-0003">Table 3</a>). One study defined hepatic late adverse effects as ALT or AST above the upper limit of normal with a prevalence of 24.5% (<a href="#CD008205-bbs2-0004">Bresters 2008</a>) (<a href="#CD008205-tbl-0004">Table 4</a>). Because unexplained heterogeneity was detected by visual inspection of the tables, we were not able to pool the results of the studies. The cancer treatment varied across the studies. In all studies, the included participants were treated with chemotherapy. The chemotherapy regimens varied considerably. In five studies, it was reported that participants were also treated with TBI and BMT (<a href="#CD008205-bbs2-0004">Bresters 2008</a>; <a href="#CD008205-bbs2-0008">French 2012</a>; <a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0021">Locasciulli 1997b</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>), but this could not explain the variation in the prevalence (5.8% to 52.8%). Selecting studies in which a considerable proportion of the participants had a chronic viral hepatitis resulted in three studies with a prevalence of elevated ALT ranging from 21.6% to 52.8% (<a href="#CD008205-bbs2-0001">Aricò 1994</a>; <a href="#CD008205-bbs2-0020">Locasciulli 1997a</a>; <a href="#CD008205-bbs2-0021">Locasciulli 1997b</a>). Although other potential sources of heterogeneity (that is, risk of bias present in the studies, age at diagnosis, follow‐up duration, gender, acute liver morbidity) also varied across these studies, they could not explain the variation in the prevalence of hepatic late adverse effects. </p> <div class="table" id="CD008205-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of ALT above the upper limit of normal</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants with hepatic late adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prevalence [95% Confidence Interval]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0001">Aricò 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.57 [14.70, 30.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0003">Bessho 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.00 [2.22, 24.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0008">French 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.70 [2.42, 26.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0010">Green 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2751</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.33 [39.50, 43.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0020">Locasciulli 1997a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.95 [21.42, 37.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0021">Locasciulli 1997b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52.83 [39.66, 65.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.66 [7.28, 10.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0028">Skou 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.77 [2.67, 12.02]</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>ALT: alanine aminotransferase.</sup> </p> </div> </div> <div class="table" id="CD008205-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of AST above the upper limit of normal</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants with hepatic late adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prevalence [95% Confidence Interval]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0008">French 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.04 [4.54, 32.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0028">Skou 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 [0.20, 6.16]</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>AST: aspartate aminotransferase.</sup> </p> </div> </div> <div class="table" id="CD008205-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of ALT or AST above the upper limit of normal</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants with hepatic late adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prevalence [95% Confidence Interval]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0004">Bresters 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.54 [19.28, 30.69]</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>ALT: alanine aminotransferase.<br/> AST: aspartate aminotransferase.</sup> </p> </div> </div> <p>Four studies defined hepatic late adverse effects as ALT above two times the upper limit of normal (<a href="#CD008205-bbs2-0016">Landier 2012</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0024">Ratner 1986</a>; <a href="#CD008205-bbs2-0025">Rossetti 1991</a>). The prevalence ranged from 0.9% to 44.8% (<a href="#CD008205-tbl-0005">Table 5</a>). Heterogeneity was also detected in these figures. Chronic viral hepatitis could partly explain the variation in the prevalence reported in <a href="#CD008205-bbs2-0025">Rossetti 1991</a> (44.8%), <a href="#CD008205-bbs2-0024">Ratner 1986</a> (23.1%), <a href="#CD008205-bbs2-0016">Landier 2012</a> (2.3%) and <a href="#CD008205-bbs2-0023">Mulder 2013</a> (0.9%), with infection rates of 62.5% (HBV), 12.8% (HBV), 8.9% (HCV), and 0% respectively. There were no differences in the risk of bias present in these studies. Although other potential sources of heterogeneity (age at diagnosis, follow‐up duration, gender, acute liver morbidity) also varied across these studies, they could not explain the variation in the prevalence of hepatic late adverse effects. </p> <div class="table" id="CD008205-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of ALT above twice the upper limit of normal</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants with hepatic late adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prevalence [95% Confidence Interval]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0016">Landier 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.28 [1.05, 4.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 [0.50, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0024">Ratner 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.08 [12.65, 38.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0025">Rossetti 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.79 [35.24, 54.75]</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>ALT: alanine aminotransferase.</sup> </p> </div> </div> <p>In addition, one study defined hepatic late adverse effects as AST above two times the upper limit of normal with a prevalence of 2.3% (<a href="#CD008205-bbs2-0016">Landier 2012</a>) (<a href="#CD008205-tbl-0006">Table 6</a>). Two studies defined hepatic late adverse effects as ALT or AST two times above the upper limit of normal with a prevalence of 7.9% and 2.7%, respectively (<a href="#CD008205-bbs2-0004">Bresters 2008</a>; <a href="#CD008205-bbs2-0016">Landier 2012</a>) (<a href="#CD008205-tbl-0007">Table 7</a>). </p> <div class="table" id="CD008205-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of AST above twice the upper limit of normal</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants with hepatic late adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prevalence [95% Confidence Interval]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0016">Landier 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.28 [1.05, 4.89]</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>AST: aspartate aminotransferase.</sup> </p> </div> </div> <div class="table" id="CD008205-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of ALT or AST above twice the upper limit of normal</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants with hepatic late adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prevalence [95% Confidence Interval]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0004">Bresters 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.87 [4.97, 12.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0016">Landier 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.66 [1.30, 5.39]</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>ALT: alanine aminotransferase.<br/> AST: aspartate aminotransferase.</sup> </p> </div> </div> </section> <section id="CD008205-sec-0064"> <h5 class="title">Billiary tract injury: γGT and ALP</h5> <p>One study investigated biliary tract injury defined as γGT above and twice above the upper limit of normal and reported a prevalence of 5.3% and 0.9%, respectively (<a href="#CD008205-bbs2-0023">Mulder 2013</a>) (<a href="#CD008205-tbl-0008">Table 8</a> and <a href="#CD008205-tbl-0009">Table 9</a>). Two studies investigated biliary tract injury defined as ALP above the upper limit of normal, with prevalences of 4.3% and 11.1% respectively (<a href="#CD008205-bbs2-0008">French 2012</a>; <a href="#CD008205-bbs2-0028">Skou 2014</a>) (<a href="#CD008205-tbl-0010">Table 10</a>). </p> <div class="table" id="CD008205-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of γGT above the upper limit of normal</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants with hepatic late adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prevalence [95% Confidence Interval]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.25 [4.16, 6.60]</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>yGT: gamma‐glutamyl transferase.</sup> </p> </div> </div> <div class="table" id="CD008205-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of γGT above twice the upper limit of normal</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants with hepatic late adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prevalence [95% Confidence Interval]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 [0.53, 1.61]</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>yGT: gamma‐glutamyl transferase.</sup> </p> </div> </div> <div class="table" id="CD008205-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of ALP above the upper limit of normal</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants with hepatic late adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prevalence [95% Confidence Interval]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0008">French 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.35 [0.77, 20.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0028">Skou 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.11 [6.32, 18.81]</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>ALP: alkaline phosphatase.</sup> </p> </div> </div> </section> <section id="CD008205-sec-0065"> <h5 class="title">Disturbance in biliary function: bilirubin</h5> <p>Three studies defined hepatic late adverse effects as bilirubin above the upper limit of normal. Prevalences ranged from 8.7% abnormal unconjugated bilirubin, 0% abnormal conjugated bilirubin (<a href="#CD008205-bbs2-0008">French 2012</a>), 1.1% abnormal total bilirubin (<a href="#CD008205-bbs2-0016">Landier 2012</a>) and 1.0% abnormal bilirubin (<a href="#CD008205-bbs2-0028">Skou 2014</a>) (<a href="#CD008205-tbl-0011">Table 11</a>). </p> <div class="table" id="CD008205-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of bilirubin above the upper limit of normal</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants with hepatic late adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prevalence [95% Confidence Interval]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0008">French 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 abnormal unconjugated bilirubin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.70 [2.42, 26.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0008">French 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 abnormal conjugated bilirubin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0016">Landier 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 abnormal total bilirubin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 [0.39, 3.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0028">Skou 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 abnormal bilirubin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 [0.17, 5.25]</p> </td> </tr> </tbody> </table> </div> <p>Because hepatic late adverse effects in the studies of <a href="#CD008205-bbs2-0002">Ballauff 1999</a>, <a href="#CD008205-bbs2-0013">Hudson 2013</a>, <a href="#CD008205-bbs2-0015">Jagt 2009</a> and <a href="#CD008205-bbs2-0033">Weber 1987</a> were defined using different assessment methods, we were not able to combine the results of these four studies. </p> <p>In four studies, liver biopsies were performed to evaluate hepatic late adverse effects in two, three, four, and ten participants, respectively (<a href="#CD008205-bbs2-0020">Locasciulli 1997a</a>; <a href="#CD008205-bbs2-0024">Ratner 1986</a>; <a href="#CD008205-bbs2-0031">Tomita 2011</a>; <a href="#CD008205-bbs2-0032">Vora 2006</a>). All liver biopsies were performed on clinical indication: persistent high ALT levels (<a href="#CD008205-bbs2-0020">Locasciulli 1997a</a>), chronic HBV infection (<a href="#CD008205-bbs2-0024">Ratner 1986</a>), fatty liver (<a href="#CD008205-bbs2-0031">Tomita 2011</a>), and splenomegaly during and soon after chemotherapy (<a href="#CD008205-bbs2-0032">Vora 2006</a>). Participants were diagnosed with either chronic persistent hepatitis, chronic lobular hepatitis, cirrhosis, portal fibrosis, nodular regenerative hyperplasia, or fatty liver. </p> </section> </section> <section id="CD008205-sec-0066"> <h4 class="title">Risk factors for hepatic late adverse effects</h4> <p>Eighteen studies investigated possible risk factors for hepatic late adverse effects (<a href="#CD008205-bbs2-0001">Aricò 1994</a>; <a href="#CD008205-bbs2-0002">Ballauff 1999</a>; <a href="#CD008205-bbs2-0004">Bresters 2008</a>; <a href="#CD008205-bbs2-0005">Chotsampancharoen 2009</a>; <a href="#CD008205-bbs2-0006">Delvecchio 2017</a>; <a href="#CD008205-bbs2-0007">El‐Rashedy 2017</a>; <a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0012">Gunn 2016</a>; <a href="#CD008205-bbs2-0013">Hudson 2013</a>; <a href="#CD008205-bbs2-0014">Hyodo 2012</a>; <a href="#CD008205-bbs2-0017">Locasciulli 1983</a>; <a href="#CD008205-bbs2-0019">Locasciulli 1991a</a>; <a href="#CD008205-bbs2-0020">Locasciulli 1997a</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0025">Rossetti 1991</a>; <a href="#CD008205-bbs2-0026">Schempp 2016</a>; <a href="#CD008205-bbs2-0030">Tefft 1970</a>; <a href="#CD008205-bbs2-0031">Tomita 2011</a>). However, only two studies (<a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>) conducted multivariable analyses. Radiotherapy involving the liver, methotrexate, mercaptopurine, thioguanine, dactinomycin, busulphan, other antimetabolites, other cytotoxic antibiotics, other alkylating agents, plant alkaloids, other chemotherapeutic agents, liver resection, BMI, alcohol intake, chronic viral hepatitis C, age at primary cancer diagnosis, age at evaluation, follow‐up time since primary cancer diagnosis, gender, metabolic syndrome, statins, and ethnicity were evaluated as possible risk factors for hepatic late adverse effects in these two studies. </p> <p>Chronic viral hepatitis (HCV, HBV, HBV‐HDV co‐infection (<a href="#CD008205-bbs2-0001">Aricò 1994</a>; <a href="#CD008205-bbs2-0002">Ballauff 1999</a>; <a href="#CD008205-bbs2-0017">Locasciulli 1983</a>; <a href="#CD008205-bbs2-0019">Locasciulli 1991a</a>; <a href="#CD008205-bbs2-0020">Locasciulli 1997a</a>; <a href="#CD008205-bbs2-0025">Rossetti 1991</a>)), cancer treatment (cyclophosphamide with TBI or TAI, cyclophosphamide with busulphan, other (<a href="#CD008205-bbs2-0004">Bresters 2008</a>); mercaptopurine, thioguanine, and/or radiotherapy involving the liver (<a href="#CD008205-bbs2-0013">Hudson 2013</a>); cranial radiotherapy (CRT) (<a href="#CD008205-bbs2-0012">Gunn 2016</a>); CRT with TBI, TBI, TAI with chemotherapy (<a href="#CD008205-bbs2-0031">Tomita 2011</a>); higher radiotherapy dose, radiotherapy field (right lobe, left lobe, entire liver, remaining liver) (<a href="#CD008205-bbs2-0030">Tefft 1970</a>); standard versus low‐dose asparaginase (<a href="#CD008205-bbs2-0007">El‐Rashedy 2017</a>)), older age at haematopoietic stem cell transplantation (HSCT), diagnosis of a benign haematological disease, gender, HSCT donor type (matched sibling donor, other), stem cell source, early post‐transplant morbidity (viral reactivation, SOS, acute GVHD) (<a href="#CD008205-bbs2-0004">Bresters 2008</a>), overweight (<a href="#CD008205-bbs2-0012">Gunn 2016</a>), iron overload (<a href="#CD008205-bbs2-0005">Chotsampancharoen 2009</a>; <a href="#CD008205-bbs2-0007">El‐Rashedy 2017</a>; <a href="#CD008205-bbs2-0026">Schempp 2016</a>), and fatty liver (<a href="#CD008205-bbs2-0014">Hyodo 2012</a>; <a href="#CD008205-bbs2-0006">Delvecchio 2017</a>) were investigated as possible risk factors for hepatic late adverse effects in univariable analyses. </p> <p>Evidence suggests that treatment with radiotherapy involving the liver (especially after a higher percentage of the liver irradiated), higher BMI, and longer follow‐up time or older age at evaluation increase the risk of cellular liver injury in multivariable analyses (<a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>). In addition, some evidence suggests that busulfan, thioguanine, hepatic surgery, higher alcohol intake (&gt; 14 units per week), chronic viral hepatitis C, metabolic syndrome, use of statins, and non‐Hispanic white ethnicity increase the risk of cellular liver injury in multivariable analyses (<a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>). Chronic viral hepatitis was shown to increase the risk of cellular liver injury in six univariable analyses as well (<a href="#CD008205-bbs2-0001">Aricò 1994</a>; <a href="#CD008205-bbs2-0002">Ballauff 1999</a>; <a href="#CD008205-bbs2-0017">Locasciulli 1983</a>; <a href="#CD008205-bbs2-0019">Locasciulli 1991a</a>; <a href="#CD008205-bbs2-0020">Locasciulli 1997a</a>; <a href="#CD008205-bbs2-0025">Rossetti 1991</a>). Moreover, there is some suggestion that treatment with radiotherapy involving the liver, higher BMI, higher alcohol intake (&gt; 14 units per week), longer follow‐up time and older age at cancer diagnosis increase the risk of biliary tract injury in multivariable analyses (<a href="#CD008205-bbs2-0023">Mulder 2013</a>). </p> <p>The identification of other risk factors has not been universally identified across all studies (see <a href="./references#CD008205-sec-0086" title="">Characteristics of included studies</a>, and additional <a href="#CD008205-tbl-0012">Table 12</a> and <a href="#CD008205-tbl-0013">Table 13</a>). </p> <div class="table" id="CD008205-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Risk factors from multivariable analyses that increase the risk of hepatic late adverse effects</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome definition ALT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk factor</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Effect size</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significant (+/‐)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0010">Green 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radiotherapy involving liver treated to ≥ 15 Gy per 10% volume increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.06 (95% CI 1.03 to 1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radiotherapy involving liver yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 2.34 (95% CI 1.07 to 5.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0010">Green 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Busulfan yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.54 (95% CI 1.02 to 2.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Busulfan yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 3.09 (95% CI 0.29 to 32.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0010">Green 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thioguanine yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.38 (95% CI 1.02 to 1.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thioguanine yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.40 (95% CI 0.38 to 5.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mercaptopurine yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.84 (95% CI 0.36 to 1.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methotrexate yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.22 (95% CI 0.53 to 2.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dactinomycin yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.71 (95% CI 0.29 to 1.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other chemotherapeutics (other antimetabolites, other cytotoxic antibiotics, other alkylating agents, plant alkaloids, other chemotherapeutic agents) yes vs no </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not significant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0010">Green 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hepatic surgery yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.90 (95% CI 1.45 to 2.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liver resection yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.87 (95% CI 0.38 to 9.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0010">Green 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BMI ≥ 25 vs &lt; 25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.60 (95% CI 1.42 to 1.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Higher BMI z‐score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.67 (95% CI 1.37 to 2.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alcohol intake of &gt; 14 units per week vs none</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 2.53 (95% CI 1.04 to 6.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alcohol intake of 7‐14 units per week vs none</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.87 (95% CI 0.33 to 2.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alcohol intake of &lt; 7 units per week vs none</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.21 (95% CI 0.63 to 2.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0010">Green 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hepatitis C grade ≥ 1 vs grade &lt; 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.76 (95% CI 1.52 to 2.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0010">Green 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Older age at evaluation per year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.01 (95% CI 1.00 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Longer follow‐up time since primary cancer diagnosis per year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.10 (95% CI 1.05 to 1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Older age at primary cancer diagnosis per year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.06 (95% CI 1.00 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gender female vs male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.18 (95% CI 0.67 to 2.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0010">Green 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metabolic syndrome yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.40 (95% CI 1.26 to 1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0010">Green 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Statins (atorvastatin, rosuvastatin, simvastatin) yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.20 (95% CI 1.02 to 1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0010">Green 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ethnicity non‐Hispanic white vs non‐Hispanic black or other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.37 (95% CI 1.18 to 1.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome definition γGT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk factor</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Effect size</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Significant (+/‐)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radiotherapy involving liver yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 5.45 (95% CI 2.51 to 11.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Busulfan yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 4.03 (95% CI 0.33 to 48.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thioguanine yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.51 (95% CI 0.09 to 2.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mercaptopurine yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.64 (95% CI0.25 to 1.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methotrexate yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.70 (95% CI 0.27 to 1.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dactinomycin yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.46 (95% CI 0.17 to 1.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other chemotherapeutics (other antimetabolites, other cytotoxic antibiotics, other alkylating agents, plant alkaloids, other chemotherapeutic agents) yes vs no </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not significant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liver resection yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.09 (95% CI 0.12 to 9.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Higher BMI z‐score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.43 (95% CI 1.14 to 1.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alcohol intake of &gt; 14 units per week vs none</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 3.04 (95% CI 1.16 to 7.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alcohol intake of 7‐14 units per week vs none</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.14 (95% CI 0.43 to 3.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alcohol intake of &lt; 7 units per week vs none</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.96 (95% CI 0.48 to 1.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Longer follow‐up time since primary cancer diagnosis per year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.13 (95% CI 1.07 to 1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Older age at primary cancer diagnosis per year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.08 (95% CI 1.01 to 1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gender female vs male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.71 (95% CI 0.38 to 1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>ALT: alanine aminotransferase.<br/> BMI: body mass index.<br/> ULN: upper limit of normal.<br/> γGT: gamma‐glutamyl transferase.</sup> </p> </div> </div> <div class="table" id="CD008205-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Risk factors from univariable analyses that increase the risk of hepatic late adverse effects</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk factor</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Significant (+/‐)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0001">Aricò 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic HCV infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0002">Ballauff 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liver function tests &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic HCV and HBV infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0017">Locasciulli 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT/AST &gt; 3 x ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cleared or persistent chronic HBV infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0017">Locasciulli 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT/AST &gt; 3 x ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Histological diagnosis of chronic hepatitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0019">Locasciulli 1991a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic HCV infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0020">Locasciulli 1997a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic HCV infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0025">Rossetti 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; 2 x ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic HBV‐HDV co‐infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0025">Rossetti 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; 2 x ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic HBV infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0013">Hudson 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT/AST/bilirubin &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High‐risk treatment exposure (mercaptopurine, thioguanine, and/or radiotherapy involving the liver) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0012">Gunn 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elevated ALT/AST; no cut‐off mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cranial radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0030">Tefft 1970</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abnormal liver function tests; no cut‐off mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radiotherapy field (right lobe, left lobe, entire liver, remaining liver)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0030">Tefft 1970</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abnormal liver function tests; no cut‐off mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radiotherapy dose (&lt; 25 Gy, 25‐35 Gy, &gt; 35 Gy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0031">Tomita 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elevated ALT/AST/γGT; no cut‐off mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment (CRT with TBI, TBI, TAI with chemotherapy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0007">El‐Rashedy 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean ALT, AST, total bilirubin, direct bilirubin values</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard‐dose asparaginase vs low‐dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0004">Bresters 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT/AST &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Conditioning regimen (cyclophosphamide with TBI/TAI, cyclophosphamide with busulphan, other) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0004">Bresters 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT/AST &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Older age at HSCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0004">Bresters 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT/AST &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis of benign haematological disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0004">Bresters 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT/AST &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gender</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0004">Bresters 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT/AST &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HSCT donor type (matched sibling donor, other)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0004">Bresters 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT/AST &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haematopoietic stem cell source (bone marrow, autologous peripheral blood, cord blood)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0004">Bresters 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT/AST &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Early post‐transplant morbidity (viral reactivation, VOD, acute GVHD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0012">Gunn 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elevated ALT/AST; no cut‐off mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overweight</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0005">Chotsampancharoen 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean ALT, total bilirubin values</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Iron overload (high serum ferritin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0007">El‐Rashedy 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean ALT, AST, total bilirubin, direct bilirubin values</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Iron overload (high serum ferritin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0026">Schempp 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elevated ALT/AST/bilirubin; no cut‐off mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Iron overload (high serum ferritin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0014">Hyodo 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elevated γGT; no cut‐off mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatty liver</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0014">Hyodo 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elevated ALT/AST; no cut‐off mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatty liver</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0006">Delvecchio 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean ALT, AST, γGT values</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatty liver</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>+: significant.<br/> ‐: not significant.<br/> ALT: alanine aminotransferase.<br/> AST: aspartate aminotransferase.<br/> CRT: cranial radiotherapy.<br/> GVHD: graft‐versus‐host disease.<br/> HBV: hepatitis B virus.<br/> HCV: hepatitis C virus.<br/> HDV: hepatitis D virus.<br/> HSCT: haematopoietic stem cell transplantation.<br/> TAI: thoraco‐abdominal irradiation.<br/> TBI: total body irradiation.<br/> ULN: upper limit of normal.<br/> VOD: veno‐occlusive disease.<br/> yGT: gamma‐glutamyl transferase.</sup> </p> </div> </div> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008205-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008205-sec-0067"></div> <p>In this update of the first systematic review, all available evidence on the association and risk of hepatic late adverse effects after treatment for childhood cancer was critically evaluated among 33 studies that met the inclusion criteria. The reported prevalence of hepatic late adverse effects varied considerably, between 0% and 84.2%. Part of this wide range could be explained by the variation in outcome definition. Selecting studies where the outcome of hepatic late adverse effects was well‐defined as ALT above the upper limit of normal, indicating cellular liver injury, resulted in eight studies. In this subgroup, the prevalence of hepatic late adverse effects ranged from 5.8% to 52.8%. A more stringent selection using an outcome definition of ALT above twice the upper limit of normal resulted in four studies, with a prevalence ranging from 0.9% to 44.8%. There is some suggestion that chronic viral hepatitis could explain a part of this variation. One study investigated biliary tract injury defined as γGT above the upper limit of normal and above twice the upper limit of normal and reported a prevalence of 5.3% and 0.9%, respectively. Three studies investigated disturbances in biliary function defined as bilirubin above the upper limit of normal and reported prevalences ranging from 0% to 8.7%. Since only two studies evaluated risk factors by multivariable analysis, there is no strong evidence regarding which paediatric patients are at the greatest risk of developing hepatic late adverse effects. There is a suggestion that radiotherapy involving the liver, including a higher irradiated volume, higher BMI, chronic viral hepatitis, and longer follow‐up time or older age at follow‐up increase the risk of cellular liver injury. In addition, there is some suggestion that busulfan, thioguanine, hepatic surgery, higher alcohol intake (&gt; 14 units per week), metabolic syndrome, use of statins, and non‐Hispanic white ethnicity increase the risk of cellular liver injury. Moreover, there is some suggestion that treatment with radiotherapy involving the liver, higher BMI, higher alcohol intake (&gt; 14 units per week), longer follow‐up time and older age at cancer diagnosis increase the risk of biliary tract injury. The studies in this systematic review showed that even many years after cancer diagnosis (&gt; 25 years), hepatic late adverse effects were still detected. Since none of the studies investigated the longitudinal development of hepatic late adverse effects many years after treatment, it is unclear if liver function recovers or deteriorates over time. </p> <p>From previous research, it is known that methotrexate, 6‐mercaptopurine, 6‐thioguanine, busulphan, and dactinomycin increase the risk of liver toxicity during or soon after cancer treatment (<a href="#CD008205-bbs2-0267">Field 2008</a>; <a href="#CD008205-bbs2-0274">King 2001</a>). It has been speculative that these chemotherapeutics also increase the risk of hepatic late adverse effects. In the current systematic review, only two studies investigated the association between individual chemotherapeutic agents and hepatic late adverse effects. One study (<a href="#CD008205-bbs2-0010">Green 2019</a>) found an association between elevated ALT levels and treatment with busulfan and thioguanine, but the other study did not find an association (<a href="#CD008205-bbs2-0023">Mulder 2013</a>). There was a great diversity in antineoplastic treatment among the participants in the other individual studies, so it was impossible to compare the effects of specific chemotherapeutics from the included studies. Hence, despite the clear association between certain chemotherapeutic agents and acute transaminase elevation, sinusoidal obstruction syndrome (SOS) and synthetic liver dysfunction (<a href="#CD008205-bbs2-0267">Field 2008</a>; <a href="#CD008205-bbs2-0274">King 2001</a>), the evidence for an increased risk of hepatic late adverse effects after treatment with methotrexate, mercaptopurine, thioguanine, busulphan or dactinomycin is less clear. </p> <p>Three included studies investigated the association between radiotherapy to the liver and hepatic late adverse effects (<a href="#CD008205-bbs2-0010">Green 2019</a>; <a href="#CD008205-bbs2-0023">Mulder 2013</a>; <a href="#CD008205-bbs2-0030">Tefft 1970</a>). <a href="#CD008205-bbs2-0010">Green 2019</a> showed that radiotherapy involving the liver is an important risk factor for cellular liver injury and that volume plays an important role. They identified a significant association between the percentage of the liver treated with ≥ 10 Gy, ≥ 15 Gy, or ≥ 20 Gy and elevated ALT .<a href="#CD008205-bbs2-0023">Mulder 2013</a> showed that radiotherapy involving the liver is an important risk factor for cellular liver injury and biliary tract injury. At a median follow‐up of 12 years after cancer diagnosis, 22 out of 123 (17.9%) cases of childhood cancer treated with radiotherapy involving the liver had abnormal ALT and/or γGT levels: 4 received TBI (7.5‐12 Gy) and 18 abdominal radiation (9‐34 Gy). <a href="#CD008205-bbs2-0030">Tefft 1970</a> reported a prevalence of abnormal liver enzyme tests of 58% in 88 childhood cancer survivors treated with radiotherapy involving the liver at a mean follow‐up of four years after the end of treatment, but it was unclear which liver enzyme tests were performed and how an abnormal test result was defined. The majority of participants were treated with a liver irradiation dose of 25 Gy or more. </p> <p>Chronic HBV and HCV infection were identified in one multivariable and six univariable analyses as risk factors for hepatic late adverse effects. Acute HBV infection in children has a variable clinical course ranging from asymptomatic state to fulminant hepatitis, with the rate of chronic infection ranging from 90% in neonates to 1% to 5% in adolescents (<a href="#CD008205-bbs2-0275">Kurbegov 2009</a>). Acute infection with HCV tends to cause mild hepatitis, yet chronic infection occurs in approximately 80% of patients (<a href="#CD008205-bbs2-0289">Villano 1999</a>). When chronically infected with HBV or HCV, patients are at risk for liver‐related morbidity and mortality from cirrhosis or hepatocellular carcinoma. In a study of <a href="#CD008205-bbs2-0264">Castellino 2004</a>, which investigated the long‐term outcomes of chronic HCV infection among survivors of childhood cancer, it was shown that at a median follow‐up of 12.4 years, 28.8% of participants had developed mild fibrosis, 35.6% moderate fibrosis, and 13.6% cirrhosis. This study was excluded from this systematic review because the study population consisted solely of hepatitis virus‐infected childhood cancer survivors. It should be noted, however, that the importance of chronic HCV infection among childhood cancer survivors is declining as the global prevalence of HCV has dramatically decreased since the introduction of effective screening of blood products in 1992 and 1993 (<a href="#CD008205-bbs2-0272">Hudson 2005</a>). </p> <p>Higher BMI, metabolic syndrome, alcohol intake, longer follow‐up time, and older age at follow‐up were also associated with an increased risk of hepatic late adverse effects. Those factors are strongly associated with liver disease in the normal population (<a href="#CD008205-bbs2-0279">Luyckx 2000</a>; <a href="#CD008205-bbs2-0280">Maddrey 2000</a>; <a href="#CD008205-bbs2-0286">Sheen 2002</a>). Although the risk of cellular liver dysfunction in childhood cancer survivors may be a reflection of an aging population prone to developing a higher BMI, and (in a subset) consuming greater units of alcohol, the increased risk is also attributable to cancer treatment. Previous studies have, for example, shown that survivors of childhood cancer are at increased risk of obesity and metabolic syndrome (<a href="#CD008205-bbs2-0281">Meacham 2005</a>; <a href="#CD008205-bbs2-0282">Meacham 2010</a>). </p> <p>Other reported risk factors were cranial radiotherapy (in one study significant, in one study not significant), standard‐dose asparaginase (compared to low‐dose, in one study significant) iron overload (in one study significant, in two studies not significant), fatty liver (steatosis) (in one study significant, in two studies not significant) older age at haematopoietic stem cell transplantation (HSCT) (in one study significant) and the diagnosis of a benign haematological disease (in one study significant); although none of the studies conducted multivariable analyses with adjustment for important prognostic factors and follow‐up. Results from univariable analyses that do not take possible confounding factors into account may lead to an overestimation of the prognostic influence of a single variable. Consequently, the results of these studies must be interpreted with caution. No studies exist in which the association between SOS or graft‐versus‐host disease (GVHD) and hepatic late adverse effects was evaluated. In addition, none of the studies in this systematic review included a control group. A control group would have allowed us to separate out the effects of important risk factors in order to determine the level of causation. </p> <p>Liver histology is the current gold standard for diagnosing liver damage but is applied conservatively in paediatric patients due to the invasive nature of the test (<a href="#CD008205-bbs2-0285">Saleh 2007</a>). Since only four studies performed liver biopsies, in a selected group of participants with clinical indications, we were not able to analyse histologically‐determined hepatic late adverse effects. Consequently, we had to focus on hepatic injury defined by elevated liver enzymes, especially serum ALT level. Although ALT is produced by other organs, it is found mainly in hepatocytes and is considered to be the most reliable and sensitive single marker of acute or subacute liver injury (<a href="#CD008205-bbs2-0273">Kim 2008</a>). Recently, <a href="#CD008205-bbs2-0284">Ruhl 2009</a> investigated whether elevated ALT levels were associated with an increased risk of all‐cause and disease‐specific mortality among 14,950 adults from the US population. Although elevated ALT was not associated with all‐cause mortality, it did relate to deaths from liver disease. An elevation in ALT was associated with a more than eight‐fold increased risk of cause‐specific mortality from liver disease. There is, however, still some doubt about the validity of serum ALT as a marker of liver disease. Elevated ALT can be asymptomatic and does not always progress to liver failure or cirrhosis. In addition, liver enzyme levels can be normal while having liver cirrhosis. Especially in the case of chronic HCV infection, normal ALT levels have been found while having liver abnormalities. So normal liver enzyme levels do not exclude the diagnosis of a chronic HCV infection and liver cirrhosis (<a href="#CD008205-bbs2-0267">Field 2008</a>; <a href="#CD008205-bbs2-0273">Kim 2008</a>). Therefore, it is difficult to judge the exact clinical consequence of hepatic late adverse effects as measured in this systematic review. Other parameters which are frequently used for liver function testing are AST, γGT, ALP, bilirubin, and coagulation times (PTT and APTT). Because the studies included in this systematic review mainly reported ALT levels, it was difficult to draw any conclusions on other measures of liver function and their relationship to long‐term liver health in childhood cancer survivors. </p> <p>After assessing the risk of bias of the included studies, which included both internal and external validity, it was obvious that all studies had methodological limitations. However, it should be noted that this assessment focused only on the evaluation of the prevalence of hepatic late adverse effects. Therefore, the quality of the included studies was only judged regarding these items. </p> <p>Internal validity gives an indication of the bias present in a study and thus how valid the results of a study are. There was an 82% risk of selection bias in studies included in this systematic review. This led to concern that an overestimation of the prevalence of hepatic late adverse effects would exist if patients with a higher risk profile were selected for the study, and an underestimation if patients with a lower risk profile were selected. In addition, the small risk of attrition bias (15%) may lead to an overestimation of the prevalence of hepatic late adverse effects if participants lost to follow‐up were in better health than those still under medical surveillance. Conversely, it would lead to an underestimation if participants lost to follow‐up were more likely to be suffering from hepatic late adverse effects, for example, because they were more frequently unable to complete the follow‐up schedule of the study. Finally, detection bias could lead to an overestimation of the prevalence of hepatic late adverse effects since knowledge of prognostic factors could increase the possibility of classifying participants as having hepatic late adverse effects. All studies in this review reported liver outcomes that were defined by absolute laboratory values. Because this could be interpreted objectively, the blinding of the outcome assessor was not important. In four studies that performed liver biopsies, it was unclear if the outcome assessors were blinded. Another potential bias was the fact that many of the included studies did not mention the actual methods of monitoring. In some studies, all participants had routine surveillance which is much more reliable and less likely to be biased as compared to ad hoc or non‐protocolised testing. </p> <p>The external validity of a study indicates how well the results of the study could be extrapolated to individual participants. There was a moderate risk of reporting bias in studies included in this systematic review. Because the study group was not well‐defined in more than half of the included studies, and only a small majority used an objective and precise outcome definition, it is difficult to interpret the results correctly. Although most of the studies reported the length of follow‐up, the median duration varied widely from 2.0 years after the end of treatment to 25.1 years since primary cancer diagnosis in studies that reported the median follow‐up duration. With short follow‐up, it is possible that the injury to the liver may be transient and reversible. With longer follow‐up, more participants would be at risk for hepatic late adverse effects. However, it was not clear whether treatment‐related increased risks of hepatic late adverse effects would continue to be raised with more prolonged follow‐up, or that the risk would level off or even decrease at some point of time. Therefore, cautious interpretation of the results is needed when the study findings are related to individual patients.   </p> <p>Variation in the studies that evaluated the prevalence of hepatic late adverse effects could also be explained by other factors. Differences in the prevalence of hepatic late adverse effects could be a reflection of different risk profiles in the study population. Factors such as chemotherapy type and dose, co‐treatment with other hepatotoxic drugs, age at diagnosis, and age at follow‐up varied considerably across the studies, which may explain the variation in the prevalence. Moreover, it should be noted that the prevalence of chronic HBV and HCV infection differed between countries and was based on the era of cancer diagnosis (<a href="#CD008205-bbs2-0272">Hudson 2005</a>). In Mediterranean countries, chronic viral hepatitis is more endemic (<a href="#CD008205-bbs2-0263">Baldo 2008</a>) so patients who received blood transfusions in these countries were at higher risk for chronic HBV or HCV infections. </p> <p>In conclusion, this systematic review showed that the prevalence of hepatic late adverse effects ranged from 5.8% to 52.8% when selecting studies with an adequate outcome definition of ALT above the upper limit of normal, indicating cellular liver injury. One study investigated biliary tract injury defined as γGT above the upper limit of normal and reported a prevalence of 5.3%. In addition, three studies investigated disturbance in biliary function defined as bilirubin above the upper limit of normal and reported prevalences ranging from 0% to 8.7%. Evidence suggests that radiotherapy involving the liver, higher BMI, chronic viral hepatitis, and longer follow‐up time or older age at follow‐up increase the risk of hepatic late adverse effects. In addition, there may be a suggestion that busulfan, thioguanine, hepatic surgery, higher alcohol intake (&gt; 14 units per week), metabolic syndrome, use of statins, non‐Hispanic white ethnicity, and older age at cancer diagnosis increase the risk of hepatic late adverse effects. </p> </section> </section> <div class="figures-list"> <div class="figure" id="CD008205-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/media/CDSR/CD008205/urn:x-wiley:14651858:media:CD008205:CD008205-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/media/CDSR/CD008205/image_t/tCD008205-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD008205-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008205.pub3/media/CDSR/CD008205/image_n/nCD008205-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/full#CD008205-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/media/CDSR/CD008205/image_n/nCD008205-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008205-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/media/CDSR/CD008205/urn:x-wiley:14651858:media:CD008205:CD008205-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/media/CDSR/CD008205/image_t/tCD008205-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008205-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008205.pub3/media/CDSR/CD008205/image_n/nCD008205-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/full#CD008205-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/media/CDSR/CD008205/image_n/nCD008205-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008205-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/media/CDSR/CD008205/urn:x-wiley:14651858:media:CD008205:CD008205-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/media/CDSR/CD008205/image_t/tCD008205-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD008205-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008205.pub3/media/CDSR/CD008205/image_n/nCD008205-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/full#CD008205-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/media/CDSR/CD008205/image_n/nCD008205-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD008205-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Risk of bias assessment criteria for observational studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Internal validity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>External validity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study group </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Selection bias (representative: yes/no)</p> <p> <ul id="CD008205-list-0001"> <li> <p>if the described study group consisted of more than 90% of the original cohort of childhood cancer survivors </p> </li> <li> <p><i>or</i> if it was a random sample with respect to the cancer treatment </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reporting bias (well defined: yes/no)</p> <p> <ul id="CD008205-list-0002"> <li> <p>if the type of chemotherapy and/or location of radiotherapy was mentioned</p> </li> <li> <p><i>and</i> if the number of participants with chronic viral hepatitis was mentioned </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Follow‐up </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Attrition bias (adequate: yes/no)</p> <p> <ul id="CD008205-list-0003"> <li> <p>if the outcome was assessed for more than 90% of the study group of interest (++)</p> </li> <li> <p><i>or</i> if the outcome was assessed for 60% to 90% of the study group of interest (+) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reporting bias (well defined: yes/no)</p> <p> <ul id="CD008205-list-0004"> <li> <p>if the length of follow‐up was mentioned</p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome     </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Detection bias (blind: yes/no)</p> <p> <ul id="CD008205-list-0005"> <li> <p>if the outcome assessors were blinded to the investigated determinant (if outcomes are biochemical measurements produced by a machine, blinding of the investigator is not relevant) </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reporting bias (well‐defined: yes/no)</p> <p> <ul id="CD008205-list-0006"> <li> <p>if the outcome definition was objective and precise, i.e. if the upper limits of normal for liver function tests were described in the definition of hepatic late adverse effects </p> </li> </ul> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk estimation </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confounding (adjustment for other factors: yes/no)</p> <p> <ul id="CD008205-list-0007"> <li> <p>if important prognostic factors (i.e. age, gender, co‐treatment) or follow‐up were taken adequately into account </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Analyses (well‐defined: yes/no)</p> <p> <ul id="CD008205-list-0008"> <li> <p>if a relative risk, odds ratio, attributable risk, linear or logistic regression model, mean difference or Chi<sup>2</sup> was calculated </p> </li> </ul> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Risk of bias assessment criteria for observational studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/full#CD008205-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008205-tbl-0002"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of ALT above the upper limit of normal</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants with hepatic late adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prevalence [95% Confidence Interval]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0001">Aricò 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21.57 [14.70, 30.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0003">Bessho 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.00 [2.22, 24.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0008">French 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.70 [2.42, 26.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0010">Green 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1137</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2751</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.33 [39.50, 43.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0020">Locasciulli 1997a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.95 [21.42, 37.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0021">Locasciulli 1997b</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52.83 [39.66, 65.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.66 [7.28, 10.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0028">Skou 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.77 [2.67, 12.02]</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>ALT: alanine aminotransferase.</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of ALT above the upper limit of normal</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/full#CD008205-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008205-tbl-0003"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of AST above the upper limit of normal</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants with hepatic late adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prevalence [95% Confidence Interval]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0008">French 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.04 [4.54, 32.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0028">Skou 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 [0.20, 6.16]</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>AST: aspartate aminotransferase.</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of AST above the upper limit of normal</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/full#CD008205-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008205-tbl-0004"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of ALT or AST above the upper limit of normal</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants with hepatic late adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prevalence [95% Confidence Interval]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0004">Bresters 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.54 [19.28, 30.69]</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>ALT: alanine aminotransferase.<br/> AST: aspartate aminotransferase.</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of ALT or AST above the upper limit of normal</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/full#CD008205-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008205-tbl-0005"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of ALT above twice the upper limit of normal</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants with hepatic late adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prevalence [95% Confidence Interval]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0016">Landier 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.28 [1.05, 4.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1362</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.88 [0.50, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0024">Ratner 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.08 [12.65, 38.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0025">Rossetti 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44.79 [35.24, 54.75]</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>ALT: alanine aminotransferase.</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of ALT above twice the upper limit of normal</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/full#CD008205-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008205-tbl-0006"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of AST above twice the upper limit of normal</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants with hepatic late adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prevalence [95% Confidence Interval]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0016">Landier 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.28 [1.05, 4.89]</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>AST: aspartate aminotransferase.</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of AST above twice the upper limit of normal</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/full#CD008205-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008205-tbl-0007"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of ALT or AST above twice the upper limit of normal</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants with hepatic late adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prevalence [95% Confidence Interval]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0004">Bresters 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.87 [4.97, 12.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0016">Landier 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.66 [1.30, 5.39]</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>ALT: alanine aminotransferase.<br/> AST: aspartate aminotransferase.</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of ALT or AST above twice the upper limit of normal</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/full#CD008205-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008205-tbl-0008"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of γGT above the upper limit of normal</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants with hepatic late adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prevalence [95% Confidence Interval]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5.25 [4.16, 6.60]</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>yGT: gamma‐glutamyl transferase.</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of γGT above the upper limit of normal</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/full#CD008205-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008205-tbl-0009"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of γGT above twice the upper limit of normal</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants with hepatic late adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prevalence [95% Confidence Interval]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1295</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.93 [0.53, 1.61]</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>yGT: gamma‐glutamyl transferase.</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of γGT above twice the upper limit of normal</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/full#CD008205-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008205-tbl-0010"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of ALP above the upper limit of normal</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants with hepatic late adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prevalence [95% Confidence Interval]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0008">French 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.35 [0.77, 20.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0028">Skou 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.11 [6.32, 18.81]</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>ALP: alkaline phosphatase.</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of ALP above the upper limit of normal</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/full#CD008205-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008205-tbl-0011"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of bilirubin above the upper limit of normal</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants with hepatic late adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prevalence [95% Confidence Interval]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0008">French 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 abnormal unconjugated bilirubin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.70 [2.42, 26.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0008">French 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0 abnormal conjugated bilirubin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0016">Landier 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 abnormal total bilirubin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.14 [0.39, 3.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0028">Skou 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 abnormal bilirubin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.96 [0.17, 5.25]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Prevalence of hepatic late adverse effects in studies with an outcome definition of bilirubin above the upper limit of normal</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/full#CD008205-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008205-tbl-0012"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Risk factors from multivariable analyses that increase the risk of hepatic late adverse effects</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome definition ALT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk factor</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Effect size</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Significant (+/‐)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0010">Green 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radiotherapy involving liver treated to ≥ 15 Gy per 10% volume increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.06 (95% CI 1.03 to 1.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radiotherapy involving liver yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 2.34 (95% CI 1.07 to 5.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0010">Green 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Busulfan yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.54 (95% CI 1.02 to 2.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Busulfan yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 3.09 (95% CI 0.29 to 32.90)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0010">Green 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thioguanine yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.38 (95% CI 1.02 to 1.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thioguanine yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.40 (95% CI 0.38 to 5.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mercaptopurine yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.84 (95% CI 0.36 to 1.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methotrexate yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.22 (95% CI 0.53 to 2.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dactinomycin yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.71 (95% CI 0.29 to 1.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other chemotherapeutics (other antimetabolites, other cytotoxic antibiotics, other alkylating agents, plant alkaloids, other chemotherapeutic agents) yes vs no </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not significant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0010">Green 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hepatic surgery yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.90 (95% CI 1.45 to 2.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liver resection yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.87 (95% CI 0.38 to 9.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0010">Green 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>BMI ≥ 25 vs &lt; 25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.60 (95% CI 1.42 to 1.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Higher BMI z‐score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.67 (95% CI 1.37 to 2.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alcohol intake of &gt; 14 units per week vs none</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 2.53 (95% CI 1.04 to 6.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alcohol intake of 7‐14 units per week vs none</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.87 (95% CI 0.33 to 2.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alcohol intake of &lt; 7 units per week vs none</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.21 (95% CI 0.63 to 2.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0010">Green 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hepatitis C grade ≥ 1 vs grade &lt; 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.76 (95% CI 1.52 to 2.02)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0010">Green 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Older age at evaluation per year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.01 (95% CI 1.00 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Longer follow‐up time since primary cancer diagnosis per year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.10 (95% CI 1.05 to 1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Older age at primary cancer diagnosis per year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.06 (95% CI 1.00 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gender female vs male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.18 (95% CI 0.67 to 2.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0010">Green 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Metabolic syndrome yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.40 (95% CI 1.26 to 1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0010">Green 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Statins (atorvastatin, rosuvastatin, simvastatin) yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.20 (95% CI 1.02 to 1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0010">Green 2019</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ethnicity non‐Hispanic white vs non‐Hispanic black or other</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.37 (95% CI 1.18 to 1.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome definition γGT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk factor</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Effect size</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Significant (+/‐)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radiotherapy involving liver yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 5.45 (95% CI 2.51 to 11.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Busulfan yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 4.03 (95% CI 0.33 to 48.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thioguanine yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.51 (95% CI 0.09 to 2.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mercaptopurine yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.64 (95% CI0.25 to 1.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methotrexate yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.70 (95% CI 0.27 to 1.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dactinomycin yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.46 (95% CI 0.17 to 1.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Other chemotherapeutics (other antimetabolites, other cytotoxic antibiotics, other alkylating agents, plant alkaloids, other chemotherapeutic agents) yes vs no </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not significant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liver resection yes vs no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.09 (95% CI 0.12 to 9.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Higher BMI z‐score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.43 (95% CI 1.14 to 1.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alcohol intake of &gt; 14 units per week vs none</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 3.04 (95% CI 1.16 to 7.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alcohol intake of 7‐14 units per week vs none</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.14 (95% CI 0.43 to 3.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alcohol intake of &lt; 7 units per week vs none</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.96 (95% CI 0.48 to 1.93)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Longer follow‐up time since primary cancer diagnosis per year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.13 (95% CI 1.07 to 1.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Older age at primary cancer diagnosis per year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 1.08 (95% CI 1.01 to 1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0023">Mulder 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>γGT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gender female vs male</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OR 0.71 (95% CI 0.38 to 1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>ALT: alanine aminotransferase.<br/> BMI: body mass index.<br/> ULN: upper limit of normal.<br/> γGT: gamma‐glutamyl transferase.</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Risk factors from multivariable analyses that increase the risk of hepatic late adverse effects</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/full#CD008205-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008205-tbl-0013"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Risk factors from univariable analyses that increase the risk of hepatic late adverse effects</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk factor</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Significant (+/‐)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0001">Aricò 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic HCV infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0002">Ballauff 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liver function tests &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic HCV and HBV infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0017">Locasciulli 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT/AST &gt; 3 x ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cleared or persistent chronic HBV infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0017">Locasciulli 1983</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT/AST &gt; 3 x ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Histological diagnosis of chronic hepatitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0019">Locasciulli 1991a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic HCV infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0020">Locasciulli 1997a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic HCV infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0025">Rossetti 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; 2 x ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic HBV‐HDV co‐infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0025">Rossetti 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT &gt; 2 x ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic HBV infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0013">Hudson 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT/AST/bilirubin &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High‐risk treatment exposure (mercaptopurine, thioguanine, and/or radiotherapy involving the liver) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0012">Gunn 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elevated ALT/AST; no cut‐off mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cranial radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0030">Tefft 1970</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abnormal liver function tests; no cut‐off mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radiotherapy field (right lobe, left lobe, entire liver, remaining liver)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0030">Tefft 1970</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abnormal liver function tests; no cut‐off mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Radiotherapy dose (&lt; 25 Gy, 25‐35 Gy, &gt; 35 Gy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0031">Tomita 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elevated ALT/AST/γGT; no cut‐off mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Treatment (CRT with TBI, TBI, TAI with chemotherapy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0007">El‐Rashedy 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean ALT, AST, total bilirubin, direct bilirubin values</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard‐dose asparaginase vs low‐dose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0004">Bresters 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT/AST &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Conditioning regimen (cyclophosphamide with TBI/TAI, cyclophosphamide with busulphan, other) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0004">Bresters 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT/AST &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Older age at HSCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0004">Bresters 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT/AST &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diagnosis of benign haematological disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0004">Bresters 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT/AST &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gender</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0004">Bresters 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT/AST &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HSCT donor type (matched sibling donor, other)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0004">Bresters 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT/AST &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haematopoietic stem cell source (bone marrow, autologous peripheral blood, cord blood)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0004">Bresters 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ALT/AST &gt; ULN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Early post‐transplant morbidity (viral reactivation, VOD, acute GVHD)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0012">Gunn 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elevated ALT/AST; no cut‐off mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overweight</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0005">Chotsampancharoen 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean ALT, total bilirubin values</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Iron overload (high serum ferritin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0007">El‐Rashedy 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean ALT, AST, total bilirubin, direct bilirubin values</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Iron overload (high serum ferritin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0026">Schempp 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elevated ALT/AST/bilirubin; no cut‐off mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Iron overload (high serum ferritin)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0014">Hyodo 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elevated γGT; no cut‐off mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatty liver</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0014">Hyodo 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elevated ALT/AST; no cut‐off mentioned</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatty liver</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="#CD008205-bbs2-0006">Delvecchio 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean ALT, AST, γGT values</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatty liver</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>+: significant.<br/> ‐: not significant.<br/> ALT: alanine aminotransferase.<br/> AST: aspartate aminotransferase.<br/> CRT: cranial radiotherapy.<br/> GVHD: graft‐versus‐host disease.<br/> HBV: hepatitis B virus.<br/> HCV: hepatitis C virus.<br/> HDV: hepatitis D virus.<br/> HSCT: haematopoietic stem cell transplantation.<br/> TAI: thoraco‐abdominal irradiation.<br/> TBI: total body irradiation.<br/> ULN: upper limit of normal.<br/> VOD: veno‐occlusive disease.<br/> yGT: gamma‐glutamyl transferase.</sup> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Risk factors from univariable analyses that increase the risk of hepatic late adverse effects</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008205.pub3/full#CD008205-tbl-0013">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008205.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008205-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008205-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008205-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD008205-note-0021">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD008205-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008205-note-0001">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD008205-note-0002">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008205\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008205\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008205\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008205\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008205\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008205\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008205\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008205\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008205\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008205\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008205\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008205\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008205\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008205\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008205\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008205\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008205\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008205\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=6iOnQIUh&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008205.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008205.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008205.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008205.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008205.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718342034"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008205.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718342037"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008205.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dcdfd3cc2935f',t:'MTc0MDcxODM0Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 